

C

P

C 司 公 有 限 公 司

B 董 事

E 董 事

M . GUAN W (C 董 事)

M . WANG L 董 事

N 董 事

M . QIN H 董 事

M . LI C 董 事

I 董 事

M . ZHONG W 董 事

M . LIU N

A 董 事

M . ZHONG W 董 事 (C 董 事)

M . LIU N

M . LI C 董 事

N 董 事

M . LIU N (C 董 事)

M . GUAN W

董 事

M . ZHONG W 董 事

M . LIU N

董 事 长 董 事 长

M . GUAN W (C 董 事)

M . ZHONG W 董 事

M . QIN H 董 事

董 事 长

M . XU N (C 董 事)

M . XU Y

M . XIE T 董 事

M . QIAN C 董 事

董 事 长

M . WANG J 董 事

M . WONG W 董 事

A 董 事

M . GUAN W

M . WONG W 董 事

A 董 事

BDO C S L P C P A LLP

L A H K L

C C 董 事

R O H O

PRC

S R 董 事

H 董 事 R 董 事

W , Z 董 事

PRC

C O N T E N T S

P R E F A C E H K

40/F, D S F C

248 Q ' R E

W

H K

H S R

C H K I S L

S 1712-1716, 17 F

H C

183 Q ' R E

W

H K

S C

2120

C ' W

.

I R

T : (86) 577 8877 1689

F : (86) 577 8878 9117

E : @ .

五、合并现金流量表

合并现金流量表

	2022 MB'000	2021 RMB'000 (R 元)	2020 RMB'000 (R 元)	2019 RMB'000	2018 RMB'000
经营活动产生的现金流量	1,484,903	1,297,430	989,012	860,692	745,972
投资活动产生的现金流量	15,605	95,691	83,509	55,523	106,910
筹资活动产生的现金流量	26,574	54,831	30,662	-17,295	-31,941
汇率变动对现金及现金等价物的影响	-10,969	40,860	52,847	38,228	74,969
现金及现金等价物净增加额	-24,221	44,036	64,961	57,289	80,596
期初现金及现金等价物余额	13,252	-3,176	-12,114	-19,061	-5,627

	2022 MB'000	2021 RMB'000 (R 元)	2020 RMB'000 (R 元)	2019 RMB'000	2018 RMB'000
购买商品、接受劳务支付的现金	2,637,787	2,377,955	2,161,262	2,117,352	1,840,724
支付给职工以及为职工支付的现金	1,311,885	1,097,676	946,349	855,843	635,451
支付的各项税费	1,325,903	1,280,279	1,214,913	1,261,509	1,205,273
支付其他与经营活动有关的现金	1,201,585	1,208,264	1,122,248	1,164,484	1,120,995
经营活动现金流出小计	124,318	72,015	92,665	97,025	84,278

注：报告期内，公司经营活动产生的现金流量净额为1,484,903元，较上年同期增加1,484,903元，主要系公司本期经营活动产生的现金流量净额较上年同期增加所致。

C 2022 2022

D S ,

F , B D W K H C , L , I
G D 31, 2022 (F 2022).

I 2022, , COVID-19 (,)
G , G I ,
G , - ,
 , ,
 .

S O P H C 2030 R
 , R
 , N P I 14 F - N H P
S C M 2022
 , I , S O
P E D D (2022-2035) O 2022 C C
C P C S C
 , -
 , G ,
 - !

D , G
 . I , G
 , D R P , G
1,107 12,172 - 3,266 .
I , ()
 , COVID-19 . M ,
G -
 - COVID-19 , COVID-19 , COVID-19
 ,
 .

I 2022, G RMB1,484.9 , 14.4% 2021, RMB1,366.8 , 13.6% 2021. L G G , Z P . T G 27 2021 29 2022 (8,728 2021 9,688 2022. W , G , , G ,

I 2022, G
G
T
,

T
L
K

F B D , I

GUAN W

C ♣ ♣

Z , PRC

A 28, 2023

O O 25, 16, C C C C P S C H

M D A

[illegible]

O S 9, 2021, S C H C N H R A P (2021-2025), 100

O J 10, 2022, 21 N D R C (NDRC) N

H C P S P 14 F -Y P ,

I ,

, ,

,

.

O A 27, 2022, G O S C 14 F -Y P N H ,
K ,
 ,
 ,
 ,
 ,
 .

O D 14, 2022, C C C P C S C O
S P E D D (2022-2035), C S C O

T G ,
G , W K H , C K H , Q K
H , Y K H Y K H . I ,
C K H , Q K H Y K H ,
 ,
 ,
 ,
P Y H , C ,

M D A

COVID-19, G
G 1,107 , 12,172 . I 2022,
3.266 . I ,
G -
COVID-19 COVID-19

I 2022, G

B H

[illegible]

I 2022, G Z P C R C P M D
Z P B N C R C M D , -
N N S F C T G
I S T C B D P A , D D
T Z P
A , G NSSI (N -S
S -I A), L G P (D ADHD D T), L T ,
K P Z P ,

() R , U , W , PRC, , , ;

M E D I A

F

T G RMB1,484.9 R P , 14.4%
2021. A , RMB1,366.8 ,
13.6% 2021. D R P ,
23.9% (2021: 25.4%). T G RMB352.9 ,
7.3% 2021. D R P ,
S C RMB-24.2 , -
2022. T S C
RMB41.1 . D R P , G
RMB227.2 (2021: RMB193.9), 17.2% 2021.

R C R

T G : () ; ()
; ()

T : :

F D 31,
2022 2021
(MB'000) (RMB'000)

T $\rightarrow$ B $\rightarrow$ R $\rightarrow$ G, $\rightarrow$

	F	D
	2022	31, 2021
	(MB'000)	(RMB'000)
B R	1,425,005	1,229,996
L : 22 22	43,545	-18
22 22 (1)	14,643	27,240
R 22 —	1,366,817	1,202,774

Note:

(1) Loss of income from special medical services refers to the estimated unrecoverable charges for offering medical services by the Group to extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "People's Government") pursuant to relevant policies.

F R P , G ' B R RMB1,425.0 , 15.9%
2021, . D R P , W
RMB43.5 , 2021. T G 2023. D R
P , RMB14.6 , RMB12.6 2021,

MEDICAL MATERIALS

TOTAL MEDICAL MATERIALS PURCHASED IN 2022, 2021 AND 2020

		FEBRUARY 2022 (MB'000)	DECEMBER 2021 (RMB'000)
		31,000	31,000
B	R	1,119,887	962,408
C		770,287	658,194
G		349,600	304,214
P			
B	R	305,118	267,588
C		269,828	238,918
G		35,290	28,670
B		1,425,005	1,229,996
C		1,040,115	897,112
G		384,890	332,884

DECEMBER 2021, B RMB1,425.0 ,

M D A

T 40
4

B R 4G

,

F 4

M D A

D R P , B R RMB1,218.3 ,
15.6% 2021, : () G ,
13.0%, - Q K H , Y K
H , T K H , W N H , W C H , P C Y
H , Y Y H J S H ; () -
G , 2.4%. T B R B R
85.5% (2021: 85.7%).

D R P , B R RMB206.7 , 17.2% 2021, 30.9% 10.5%. T 14.5% (2021: 14.3%).

D R P , B R 16.4% 2021, 78.6% (2021: 78.2%)

B R ; B R 14.0%

2021, 21.4% (2021: 21.8%) B R , :

12.8% (2021: 13.8%),

71.9% (2021: 69.3%).

C G ,

T G :

	F	D
	2022	2021
	(MB'000)	(RMB'000)
P	339,777	310,090
E	390,107	321,207
D	33,584	42,283
D	99,553	75,386
C	63,747	53,470
T	27,588	25,595
O	85,759	69,081
C	1,040,115	897,112

Management Discussion and Analysis

During the reporting period, the Company's operating income was RMB1,040.1 million, an increase of 15.9% compared with the same period of 2021. The operating profit was RMB159.5 million, an increase of 9.6% compared with the same period of 2021. The net profit attributable to shareholders was RMB104.0 million, an increase of 21.5% compared with the same period of 2021. The basic earnings per share was RMB1.04, an increase of 32.1% compared with the same period of 2021.

The Company's operating profit margin was 32.7% (2021: 34.6%). The net profit margin was 37.5% (2021: 35.8%). The Company's operating profit margin was 12.8% (2021: 13.1%).

The Company's operating profit margin was 32.7% (2021: 34.6%). The net profit margin was 37.5% (2021: 35.8%). The Company's operating profit margin was 12.8% (2021: 13.1%).

The Company's operating profit margin was 32.7% (2021: 34.6%). The net profit margin was 37.5% (2021: 35.8%). The Company's operating profit margin was 12.8% (2021: 13.1%).

The Company's operating profit margin was 32.7% (2021: 34.6%). The net profit margin was 37.5% (2021: 35.8%). The Company's operating profit margin was 12.8% (2021: 13.1%).

	F	D	31,
	2022		2021
T	27.4%		29.6%
P	11.6%		10.7%
O	23.9%		25.4%
P	22.2%		24.7%
C	23.8%		25.4%

MEDICAL MATERIALS

During the period, the company's medical materials business revenue decreased by 23.8% (2021: 25.4%), and the gross profit margin decreased by 2.2 percentage points. The company's medical materials business revenue in 2021 was RMB43.6 million.

Medical Materials

During the period, the company's medical materials business revenue decreased by RMB5.0 million (2021: RMB5.8 million).

Sales

During the period, the company's medical materials business revenue decreased by RMB15.0 million (2021: RMB10.3 million). The company's medical materials business revenue decreased by 1.1% (2021: 0.9%).

Assets

During the period, the company's medical materials business revenue decreased by RMB15.0 million (2021: RMB10.3 million). The company's medical materials business revenue decreased by 1.1% (2021: 0.9%).

	Fiscal Year	December 31,
	2022	2021
	(MB'000)	(RMB'000)
Employee compensation and benefits	111,252	100,510
Depreciation and amortization	24,761	22,117
Cost of sales	29,187	13,014
Transportation	4,359	2,835
Others	36,328	37,896
	205,887	176,372

During the period, the company's medical materials business revenue decreased by RMB205.9 million (2021: RMB13.5 million). The company's medical materials business revenue decreased by 16.7% (2021: 15.1%). The company's medical materials business revenue decreased by 15.1% (2021: 14.7%).

D R P , G ' 6 6 V 7 8 9 RMB33.0 (2021:

MEDICAL MATERIALS

During the period, the company purchased medical materials for RMB44.3 million, compared with RMB6.7 million in 2021, an increase of 551.1%. The increase was mainly due to the purchase of medical materials for the new hospital building. The company purchased medical materials for RMB2.4 million in 2021.

At the end of the period,

the company's inventory of medical materials was RMB1.2 million, compared with RMB0.8 million in 2021, an increase of 50%. The increase was mainly due to the purchase of medical materials for the new hospital building.

	Fiscal Year 2022 (RMB'000)	Fiscal Year 2021 (RMB'000)
Medical materials	31,159	20,875
Medical equipment	-15,927	-6,566
Medical supplies	18,063	7,075
Medical services	714	6,429
	2,850	6,938

During the period, the company purchased medical equipment for RMB2.9 million, compared with RMB15.9 million in 2021, a decrease of 81.1%. The decrease was mainly due to the purchase of medical equipment for the new hospital building. The company purchased medical equipment for RMB15.9 million in 2021.

At the end of the period,

the company's inventory of medical equipment was RMB25.2 million (2021: RMB2.1 million), an increase of 1,100%. The increase was mainly due to the purchase of medical equipment for the new hospital building.

At the end of the period,

the company's inventory of medical supplies was RMB10.3 million, compared with RMB10.3 million in 2021, an increase of 0%. The increase was mainly due to the purchase of medical supplies for the new hospital building.

MEDICAL MATERIALS

Notes: 1. The company's medical materials are mainly used in the company's medical services.

2. The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services.

	Fiscal Year 2022 (MB'000)	Fiscal Year 2021 (RMB'000)
Medical materials	31,000	31,000
Medical materials	55	266
Medical materials	7,436	9,470
Medical materials		1,800
Medical materials	1,063	300
Medical materials	8,554	11,836
Medical materials	1,588	166
Medical materials	3,928	3,333
Medical materials	1,754	1,399
Medical materials		2,000
Medical materials	2,071	1,739
Medical materials	9,341	8,637

The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services.

Notes: 1. The company's medical materials are mainly used in the company's medical services.

2. The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services. The company's medical materials are mainly used in the company's medical services.

MEDICAL MATERIALS

Finished Products

Inventory

At December 31, 2022, the ending balance of inventory was RMB58.3 million (at December 31, 2021: RMB56.5 million), an increase of 3.8% over the ending balance of the prior year.

Accounts Receivable

At December 31, 2022, the ending balance of accounts receivable was RMB382.8 million (at December 31, 2021: RMB311.8 million), an increase of 22.8% over the ending balance of the prior year. The increase was mainly due to the growth of sales.

During the reporting period, the company's accounts receivable turnover was 4.2 times (2021: 3.7 times).

Other Receivables and Prepayments

At December 31, 2022, the ending balance of other receivables and prepayments was RMB69.4 million (at December 31, 2021: RMB41.8 million).

Other Non-current Financial Assets

At December 31, 2022, the ending balance of other non-current financial assets was RMB63.1 million (at December 31, 2021: RMB65.8 million). During the reporting period, the company's other non-current financial assets decreased by RMB2.7 million, mainly due to the decrease in the balance of long-term equity investments.

Cash

At December 31, 2022, the ending balance of cash was RMB152.5 million (at December 31, 2021: RMB43.8 million), an increase of 246.8% over the ending balance of the prior year. The increase was mainly due to the company's strong operating performance and the receipt of government subsidies.

Prepaid Expenses

At December 31, 2022, the ending balance of prepaid expenses was RMB190.4 million (at December 31, 2021: RMB257.4 million), a decrease of 25.9% over the ending balance of the prior year. The decrease was mainly due to the expiration of the prepaid expenses.

Accounts Payable

At December 31, 2022, the ending balance of accounts payable was RMB85.8 million (at December 31, 2021: RMB69.2 million).

MEDICAL MATERIALS

Raw Materials and Consumables

As of December 31, 2022, the carrying amount of Raw Materials and Consumables was RMB 29.9 million, compared with RMB 16.3 million as of December 31, 2021.

Other Payables

As of December 31, 2022, the carrying amount of Other Payables was RMB 72.2 million, compared with RMB 57.3 million as of December 31, 2021. The carrying amount of Other Payables was RMB 17.0 million as of December 31, 2021.

Long-term Contract

The carrying amount of Long-term Contract was RMB 227,221 thousand as of December 31, 2022, compared with RMB 193,896 thousand as of December 31, 2021.

	December 31, 2022	December 31, 2021
	(RMB'000)	(RMB'000)
Raw Materials and Consumables	227,221	193,896
Other Payables		

M E D I C A L

Non-communicable diseases (NCDs) are the leading cause of death and disability worldwide. In 2019, NCDs accounted for 71% of the total deaths in China, with a total of 10.9 million deaths. The leading causes of death were cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. The burden of NCDs is increasing rapidly, and it is expected to continue to rise in the future. The World Health Organization (WHO) has identified NCDs as a major public health challenge, and has called for a global strategy to reduce their burden. The strategy includes promoting healthy lifestyles, strengthening surveillance and early detection, and improving the quality of care for NCDs. In China, the government has implemented a series of measures to reduce the burden of NCDs, including strengthening surveillance and early detection, improving the quality of care, and promoting healthy lifestyles. These measures have led to a significant reduction in the burden of NCDs in China, but there is still a long way to go. The government needs to continue to strengthen its efforts to reduce the burden of NCDs, and to ensure that everyone has access to the care they need.

INVESTMENT

Investment in medical research and development (R&D) is a key driver of innovation and progress in the medical field. In 2022, the company invested RMB616.5 million in R&D, an increase of 10.2% compared with RMB553.2 million in 2021. The investment was primarily used for the development of new drugs, medical devices, and diagnostic tests. The company also invested in the development of new clinical trials and the recruitment of new clinical trial subjects. The investment in R&D has led to a significant increase in the number of new drugs, medical devices, and diagnostic tests developed by the company. The company has also made significant progress in the development of new clinical trials and the recruitment of new clinical trial subjects. The investment in R&D has led to a significant increase in the number of new drugs, medical devices, and diagnostic tests developed by the company. The company has also made significant progress in the development of new clinical trials and the recruitment of new clinical trial subjects.

M E T H O D S

Exchange Rates

The Group uses the closing exchange rates of the Hong Kong dollar (HKD) to the Renminbi (RMB) to convert the financial statements of the subsidiaries and associates.

As at December 31, 2022, the Group's financial statements are presented in RMB. The Group's financial statements are presented in RMB. The Group's financial statements are presented in RMB.

Goodwill

As at December 31, 2022, the Group's goodwill is measured at cost less impairment. The Group's goodwill is measured at cost less impairment. The Group's goodwill is measured at cost less impairment.

Employee Benefits

As at December 31, 2022, the Group's employee benefits are measured at cost less impairment. The Group's employee benefits are measured at cost less impairment. The Group's employee benefits are measured at cost less impairment.

Share-based Payments

The Group's share-based payments are measured at cost less impairment. The Group's share-based payments are measured at cost less impairment. The Group's share-based payments are measured at cost less impairment.

M E D I A

I E I S , 165 ,
1,818,529 T 23
, 180,516 T ()
13 , 540,229 . A ,
8 , 79,274 . A ,
E I S 193 , 2,460,000
T 3.2976%
C T 48
RMB10.47/ .

T E I S :

(1) P

T E I S
C C - ,
G , S , C
C C -
C T E I S
S
C I A A .

(2) S P

(a) S P
A P G E I S .
G E I S .
P D , S , G ()
, () , B ,
B P E I S 36
E I S .

() L P E I S
T P
B .

M 2022 D 2021 A

- (3) D 2022 2021 E 2021 S
- (4) F 2022 2021 E 2021 S
T C 2022 2021 , 2022 2021 I 2021 S 2022 2021
2022 2021 . W I 2021 S 2022 2022 2022 2022 , 2022 2022
2022 S 2022 C 2022 T P 2022 2022 ,
2022 I 2021 S 2022 - 2022 . I 2021 S 2022
2022 P 2022 2022 ,
2022 . T 2022 -
2022 . U 2022 - , 2022 , P 2022 2022
2022 I 2021 S 2022 2022
P 2022 .
- () S 2022 2022 S 2022 E 2021 S 2022
T I 2021 S 2022 E 2021 S 2022 - 2022 - D
S 2022 , 2022 C 2022
- () A 2022 2022 E 2021 S 2022 2022
2022 C 2022
P 2022 2022 2,460,000 S 2022 E 2021 S 2022 ,
3.30% C 2022 2022 2022 2022 , 2022
4.45% - 2022 - D S 2022 .

M D A

$$(4) \quad V_{\mathcal{A}} = \bigoplus_{i=1}^n V_{\mathcal{A}}^i, \quad \text{where } V_{\mathcal{A}}^i = \{v \in V_{\mathcal{A}} \mid E(v) = i\} \text{ and } S = \{v \in V_{\mathcal{A}} \mid E(v) = 1\}.$$

(a)  10

() L - E I S
T - I S Po 48 ,
Po I S .

() U E I S
I S 48 (J 28, 2022)
(J 29, 2018); I S
E I S

$$(5) \quad G \rightarrow E \rightarrow I \rightarrow S$$

() T P P P

() T C  D  N  P  G  D .

() T P D N C

(v) W I S C P

(f) T C $\rightarrow$ E I S
P , P , S
 , ,
P , .

M I N D A

- (6) *G P E I S* *S*
- (7) *G P E I S T G P I S* *RMB10.47 S ; T G P I S RMB10.47 S*
- () *B G P E I S C I S* *B S , G P RMB10.47 E I S*

M D A

F S D 31, 2022, I S E I

Figure 1. The 1000 Genomes Project. The 1000 Genomes Project is a large-scale genomics project that aims to create a comprehensive reference of human genetic variation. The project involves sequencing the genomes of 1,000 individuals from diverse populations. The data generated is used to identify common and rare genetic variants across the human population. The project is a collaborative effort involving researchers from various institutions and countries. The data is made available to the public through the 1000 Genomes Project website. The project has a significant impact on the field of genetics and genomics, providing a valuable resource for researchers and clinicians alike.

D										
M . WANG L ()	J 18, 2021	35.95	J 28, 2022	10.47	248,328	-	248,328	-	-	-
M . WANG H ()	J 18, 2021	35.95	J 28, 2022	10.47	95,511	-	95,511	-	-	-
S										
M . SUN F ()	J 18, 2021	35.95	J 28, 2022	10.47	14,327	-	14,327	-	-	-
M . XIE T	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
O										
M . XU Y (M . WANG H)	J 18, 2021	35.95	J 28, 2022	10.47	28,653	-	28,653	-	-	-
M . WANG B (M . WANG L M . WANG H)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . XU Q (M . XU Y)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . GUAN W (M . GUAN W)	J 18, 2021	35.95	J 28, 2022	10.47	19,102	-	19,102	-	-	-
M . SUN H (M . WANG L M . WANG H)	J 18, 2021	35.95	J 28, 2022	10.47	30,563	-	30,563	-	-	-
M . ZHANG L (M . GUAN W)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-

T C

Report of the Board

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has reviewed the financial statements of the Company for the year ended December 31, 2022.

The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2022.

The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2022. The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2022. The Board of Directors of the Company has reviewed the financial statements of the Company for the year ended December 31, 2022.

C R L R

T C , ,
PRC C L , H K L R , SFO, H K C O ,
S , , C T C
B D .

L G M
H L PRC (《中華人民共和國精神衛生法》), L P ' R C P
B M H G (《中華人民共和國基本醫療衛生與健康促進法》) (J 1, 2020),
M R M I (《醫療機構管理條例》) R I
M R M I (《醫療機構管理條例實施細則》).

T G . I
.

T C . T D
G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

Report of the Board

Director's Report

This report summarizes the business performance of Wenzhou Kangning Hospital Co., Ltd. (the "Company") for the period from January 1, 2022, to December 31, 2022.

Business Performance

In accordance with the provisions of the Company Law of the People's Republic of China (《中華人民共和國企業所得稅法》), the Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified accounting firm. The Company's financial statements are prepared in accordance with the accounting standards of the People's Republic of China.

In accordance with the provisions of the Company Law of the People's Republic of China, the Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified accounting firm. The Company's financial statements are prepared in accordance with the accounting standards of the People's Republic of China.

The Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified accounting firm. The Company's financial statements are prepared in accordance with the accounting standards of the People's Republic of China.

S G

D C R P N V
F S - (XXXIII) .

R

D G R P C S
C O 'E N V F S - (XXXIV), (XXXV) (XXXVI)
.

D R

Report of the Board

DIRECTORS' REPORT

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its duties in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

1. Review of the Company's Business Performance

For the period from January 1, 2022, to December 31, 2022, the Company has completed its business performance in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

2. Financial Performance

For the period from January 1, 2022, to December 31, 2022, the Company has completed its financial performance in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

3. Shareholder Returns

For the period from January 1, 2022, to December 31, 2022, the Company has completed its shareholding returns in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

4. Other Matters

The Board of Directors has completed its duties in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

5. Board of Directors' Resolutions

M. GUAN W (Chairman)

M. WANG L (Vice Chairman)

M. WANG H (Secretary) (Term expires December 31, 2022)

6. Board of Directors' Resolutions

M. QIN H

M. LI C

7. Board of Directors' Resolutions

M. ZHONG W

M. LIU N

M. ZHAO X (Term expires March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (,17, 2022)

B R A K I F P

F , G D 31, 2022, F H M D A

D ' S ' I T , A C

S R B - C T N F S - R
C ,
D S , D S ,
D 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R
C S
G C

M C

D R P , C
C

Report of the Board


N - A

P / G G N - A D 31, 2022, C S P) C S .

T C A D D 31, 2022. C S N - 31, 2022 S , N - A

D
E

P D , N F S - R C G
 D 31, 2022 N C
 R T C G

N D  R P .

D ' I C B

D R P , D H K L

Figure 1. The structure of the proposed model. The model is composed of three parts: the input layer, the hidden layer, and the output layer. The input layer consists of the input variables $X_1, X_2, \dots, X_n$. The hidden layer consists of the hidden variables $h_1, h_2, \dots, h_m$. The output layer consists of the output variables $Y_1, Y_2, \dots, Y_k$. The model is trained using the backpropagation algorithm.

Report of the Board

I S S

A D 31, 2022, C S 336 SFO
D, S C D /
C H K S E D 2 3 P XV SFO,
5%
C

A, A,
P P
S C ,
I I

姓名	職銜	國籍	身份	持有本公司股份數(股)	持有本公司股份比例	是否為一致行動人
陳慶瑞	董事長	中國	董事	7,466,666(L)	13.51%	10.00%
中國鄉村產業投資基金股份有限公司(中央企業鄉村產業投資基金股份有限公司)(中國鄉村產業投資基金股份有限公司)						
孫建國	總經理	中國	董事	4,540,000(L)	8.22%	6.09%
上海金浙企業管理中心(有限合夥)(上海金浙企業管理中心(有限合夥)) ⁽²⁾						
FAN Y ⁽²⁾		中國	董事	4,540,000(L)	8.22%	6.09%
SUN J ⁽²⁾		中國	董事	4,540,000(L)	8.22%	6.09%
孫建國	總經理	中國	董事	4,540,000(L)	8.22%	6.09%
上海金浦健服股權投資管理有限公司 ⁽²⁾						
溫州金寧股權投資合夥企業(有限合夥)(溫州金寧股權投資合夥企業)			董事	4,540,000(L)	8.22%	6.09%
XU Y ⁽⁶⁾		中國	董事	5,785,350(L)	10.47%	7.76%
上海檀英投資合夥企業(有限合夥)		中國	董事	4,519,003(L)	8.18%	6.06%

Name	Company	Shareholding Ratio	Investment Type	Investment Amount (RMB)	Investment Date	Current Investment Amount (RMB)	Current Investment Percentage (%)	Current Investment Percentage (%)
S... L... I... L.P. D	S... I			4,519,003(L)		8.18%	6.06%	
(上海樂進投資合夥企業(有限合夥)) ⁽³⁾								
LIN L	D	S... I		6,506,309(L)		11.77%	8.72%	
S... L... V... I... M... C., L	D	S... I		6,506,309(L)		11.77%	8.72%	
(上海正心谷投資管理有限公司) ()								
S... S... I... M... C., L) ⁽⁴⁾								
W I... C., L . (萬得 D	S... I			3,333,000(L)		6.03%	4.47%	
信息技術股份有限公司)								
S... H... E D	S... I			3,333,000(L)		6.03%	4.47%	
M... C (L P...) (上海荷花緣企業								
管理中心(有限合夥))								
W I... E... I... D	S... B			3,333,000(L)		6.03%	4.47%	
(J...) P... (L P...) (萬得影響力股權								
投資(嘉興)合夥企業(有限合夥))								
(W I...)								
Q... J... H... I... D	S... B			2,780,000(L)		5.03%	3.73%	
C., L . (青島金石灝納投資有								
限公司)								
J... I... C., L . (金石 D	S... I			2,780,000(L)		5.03%	3.73%	
投資有限公司) ⁽⁵⁾								
O M A... LLC	H S			1,454,000(L)		7.52%	1.95%	
O M C... LLC	H S			2,150,900(L)		11.12%	2.88%	
O M P... M... F	H S			1,279,900(L)		6.62%	1.72%	
L								
O M P... II, L.P.	H S			1,052,000(L)		5.44%	1.41%	
UBS G AG	H S			1,029,400(L)		5.32%	1.38%	
ZOU H... (鄒海麗)	H S			1,680,000(L)		8.69%	2.25%	
M . WANG H 6 T 02 (S... 977 5.247 118.6926 176.833.73445 64)								

Report of the Board

N :

(L): L

- (1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.
- (2) FAN Y 50% S J E M C (L P) (上海金浙企業管理中心(有限合夥)) S J E M C (L P) (上海金浙企業管理中心(有限合夥)) W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J E I P (L P). T , XV SFO, FAN Y , S J E M C (L P) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I M C , L . (上海金浦健服股權投資管理有限公司) D S W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)) C
- (3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (4) S L V I M C , L (上海正心谷投資管理有限公司) (S S I M C , L (上海盛歌投資管理有限公司)) S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L V I M C , L D S S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (5) Q J H I C , L . (青島金石灝沏投資有限公司) J I C , L . (金石投資有限公司). T , J I C , L . (金石投資有限公司) D S Q J H I I C , L . (青島金石灝沏投資有限公司) C J XV SFO.
- (6) M . WANG H J N X K I M L.P. N E K I M P (L P) 50.62% 37.10%, , XV SFO, M . WANG H J D S M . XU Y M . WANG H . M . XU Y D S M . WANG H J XV SFO.

S , D 31, 2022, D , (D , S C , D 2 3 P XV SFO, C S 336 SFO.



T (BDO), BDO C, S, L, P, C, P, A, LLP

A D 16, 2022, BDO A C B 2021 C H S C C 2022 C PRC A S , B E , C 2022 C

F       , 

Report of the Board

(2) C 2020

(Unit: RMB,)

I.	A	C	B
O	63,465,824	-12,878	63,478,702
T	542,683,617	-12,878	542,696,495
T	2,161,261,775	-12,878	2,161,274,653
O	76,603,400	-9,203,741	85,807,141
T	606,077,103	-9,203,741	615,280,844
T	946,349,216	-9,203,741	955,552,957
U	214,856,099	9,190,863	205,665,236
T	1,122,247,550	9,190,863	1,113,056,686
T	1,214,912,559	9,190,863	1,205,721,695
T	2,161,261,775	-12,878	2,161,274,653

(3) C 2021

(Unit: RMB,)

I.	A	C	B
O	29,925,488	-12,878	29,938,366
T	609,602,623	-12,878	609,615,501
T	2,377,954,989	-12,878	2,377,967,867
O	57,319,524	-9,203,741	66,523,265
T	535,774,635	-9,203,741	544,978,376
T	1,097,675,868	-9,203,741	1,106,879,609
I	6,937,845	-12,878	6,950,723
U	257,098,624	9,190,863	247,907,761
T	1,208,263,897	9,190,863	1,199,073,034
T	1,280,279,120	9,190,863	1,271,088,257
T	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

T - 56 \ C \ A S B E . T \ C \ T , - 56 \ .

Opinions of the Board

T B \ C \ A A , \ C \ T B \ .

Opinions of the Supervisory Committee

T S \ C \ , , \ C \ T S \ C .

Opinions of the Audit Committee

T A C \ A S B E , \ C \ T A C .
T \ N XV F S -O \ .

C S T

Figure 1 illustrates the experimental design with two scenarios, A and B. Each scenario compares a Control group and a Treatment group. In Scenario A, the Control group has a 100% success rate (S) and the Treatment group has a 50% success rate (S). In Scenario B, the Control group has a 50% success rate (S) and the Treatment group has a 100% success rate (S). The success rate is indicated by the number of 'S' symbols relative to the total number of symbols in each group.

F ♀ ♀ B ♀
GUAN W
C ♀ ♀

Z , PRC
A 14, 2023

T S :

I 2022, S C , PRC C L , A ,
S C , T B , S
C ,
D C S .

D R P , S C B , C
C C

T S C - C R
P , D B ,

I 2023, S C -
. T , S C
, S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

一、基本情况

（一）公司治理结构

公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立公正地履行职责，积极建立健全内部控制体系，保护投资者合法权益，维护公司规范运作，促进公司持续健康发展。

Corporate Governance Report

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors has reviewed the Company's financial statements and the related reports prepared by the management, and has confirmed that the financial statements are true and accurate, and that the related reports are complete and accurate. The Board of Directors has also reviewed the Company's business performance and the related reports prepared by the management, and has confirmed that the business performance is true and accurate, and that the related reports are complete and accurate.

The Board of Directors has also reviewed the Company's internal control system and the related reports prepared by the management, and has confirmed that the internal control system is effective and that the related reports are complete and accurate. The Board of Directors has also reviewed the Company's risk management system and the related reports prepared by the management, and has confirmed that the risk management system is effective and that the related reports are complete and accurate.

In addition, the Board of Directors has also reviewed the Company's environmental, social and governance (ESG) performance and the related reports prepared by the management, and has confirmed that the ESG performance is true and accurate, and that the related reports are complete and accurate.

The Board of Directors has also reviewed the Company's human resources management and the related reports prepared by the management, and has confirmed that the human resources management is effective and that the related reports are complete and accurate.

The Board of Directors has also reviewed the Company's information management and the related reports prepared by the management, and has confirmed that the information management is effective and that the related reports are complete and accurate.

REPORT OF THE SUPERVISORY BOARD

Corporate Governance Report

C♯, D, S, ♭, C, E♭, ♭

O D 31, 2021, , M . WANG H , M . JIN H C J 10, 2022.

October 17, 2022, 10:58 AM, M. CHEN J. CHEN

O F 15, 2022, S C

O F 19, 2022, C M . XU N

O J 12, 2022, M. NG W S C (1) C ,
(A R 4T) C H KH 4T T 0 16 C DO 622 C L D KH

On July 5, 2023, C. WANG L. (M.), D., M. W. 100,000 S C M. W. J., C RMB13.28 S D 19, 2022 (D). P D, M. W. / B D C A M. W. S C B - P C C, C M. W. , A.3 B.8 M C.

Corporate Governance Report

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。

- (1) 报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。
- (2) 报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。
- (3) 报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。

报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。

报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。

报告期内，公司董事会、监事会、高级管理人员严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，切实维护公司全体股东和债权人的合法权益。

Corporate Governance Report

C

O Ma 10, 2023, , M . ZHAO X , B . F , M . ZHAO X , H K L R 3.10 R 3.25 H K L R ; () R 3.27A H K L R . O Ma 10, 2023, B . A C M . JIN L M . JIN L Ma 10, 2023.

S , B CG C R P .

S C D S

E D (- D) S C T D S A , . N C , .

A S

T C C A S B E 2017, C O (C 622 H K) (C O).

A P

A P

T A S B E - B S , M F F 15, 2006 (A B E).

T . T H K C O H K C O .

Corporate Governance Report

C A P

T ♀ ♀ ♀ ♀ N III (XXXI) F ♀ ♀ S ♀ - S ♀

♀ ♀ ♀ ♀ ♀ ♀

A B M G M

T C B C.5.1 CG C . N B C.5.3 CG

D R P , C 11 B D B

E	D	
M. GUAN W	(C	11/11
M. WANG L		11/11
M. WANG H	(S 1, 2022)	5/5

N	-	D	
M	.	QIN H	11/11
M	.	LI C	11/11

International Journal of Data Science and Analytics	
M. ZHAO X	(11/11)
M. ZHONG W	(11/11)
M. LIU N	(11/11)

A D          . T   , , C C

Figure 1 displays Feynman diagrams for the decay of a scalar particle M into two photons. The diagrams are arranged in two rows. The top row shows diagrams for the decay $M \rightarrow \gamma\gamma$ via a fermion loop (labeled B) and a scalar loop (labeled D). The bottom row shows diagrams for the decay $M \rightarrow \gamma\gamma$ via a fermion loop (labeled B) and a scalar loop (labeled D). The diagrams are labeled M , B , D , and T .

Corporate Governance Report

Director, Mr. Guan W (Chairman), Mr. Wang L, Mr. Wang H, Mr. Qin H, Mr. Li C, Mr. Zhao X, Mr. Zhong W, Mr. Liu N

1/1

1/1

1/1

1/1

0/0

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

1/1

Corporate Governance Report

B C

T B $\rightarrow$ $\rightarrow$, $\rightarrow$ A C , N $\rightarrow$ C , R $\rightarrow$
C $\rightarrow$ S $\rightarrow$ R M $\rightarrow$ C , $\rightarrow$ $\rightarrow$ $\rightarrow$ $\rightarrow$ B $\rightarrow$ C $\rightarrow$
A B $\rightarrow$ C $\rightarrow$ $\rightarrow$
H K S E $\rightarrow$ $\rightarrow$ $\rightarrow$ C $\rightarrow$ $\rightarrow$ $\rightarrow$ $\rightarrow$

A C

T C A C R 3.21 R 3.22 H K L
R , CG C A
C B .T , A C
; ;
; ;
; ;
B .

A, A C - D, M. ZHONG
W (A C) M. LIU N, - D, M. LI C . F
A C R P, ,
2021 2022 G.

T D A C R P :

N

D...

1

M. ZHONG W. (C.)

5/5

M. LIU N

5/5

M . L I C ♣ ♣

5/5

Corporate Governance Report

一、公司治理

本公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

M. LIU N (C)	2/2
M. GUAN W	2/2
M. ZHAO X (M 10, 2023)	2/2

报告期内，公司严格按照《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的要求，不断完善公司治理结构，规范公司运作，提高公司治理水平，促进公司持续、健康发展。

Corporate Governance Report

R C

T C R C R C B . T CG C
R C D
D
D
;
,
C 17 H K L R ;
C
B .

A, R C - D, M. ZHONG W M. LIU N. T R C E.1.2() CG C (. . B D). O R C R P, C 2021.

T D R C R P

⋮

D

M . ZHAO X	(C 审 终) (民 10, 2023)	1/1
M . ZHONG W	审	1/1
M . LIU N		1/1

T  G  D  C  T  D  B  .

T D 31, 2022 N F S -

Corporate Governance Report

S  R  C
T C   S  R  C

Corporate Governance Report

), C, C, B

A	G	D
30 – 49  (3)	F  (33.3%)	1 – 5  (4)
50 – 59  (3)	M  (66.7%)	6 – 10  (2)

T B 2 D 4 D . T B C B . T N B

G D W

A D 31, 2022, G 4,196 (), 66.63%
 33.37%. T G R M M
 《招錄管理辦法》). D , G , ,

C G F

T B a

(a) $\nabla C \nabla_{\mathcal{Y}} \nabla \text{CG} C \nabla \nabla$;

() $\nabla \nabla C \nabla_{\mathcal{Y}} \nabla \nabla \nabla \nabla$;

() $\nabla, \nabla \nabla D \nabla \nabla$;

() $\nabla \nabla \nabla D, S \nabla \nabla$;

() $\nabla \nabla C \nabla_{\mathcal{Y}} \nabla \nabla \nabla \nabla \nabla \nabla$;

D R P , B , , D ; (2)

D , S ; (3)

; (4)

Corporate Governance Report

Director's Report on Corporate Governance

The Board of Directors has been fully aware of the importance of corporate governance and has taken a series of measures to improve the corporate governance system. In 2022, the Board of Directors has completed the annual work report on corporate governance, which is available on the company's website. The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system.

The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system.

The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Board of Directors has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system.

Management's Report on Corporate Governance

The Management has been fully aware of the importance of corporate governance and has taken a series of measures to improve the corporate governance system. In 2022, the Management has completed the annual work report on corporate governance, which is available on the company's website. The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system.

The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system. The Management has also organized the company's internal control system and risk management system, and has taken a series of measures to improve the company's corporate governance system.



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

O J 12, 2022, M . NG W S , SWCS C S G (H K) L , M . WONG W

C S I R

$$S \rightarrow R$$

I B  EGM   

, S    10% S 

S  C  EGM  .

S    B   C  

Corporate Governance Report

C 董 C 董 D

D R P , A .

D P

T C 10% C C 50% C S C , A C , S A . S C N S

T C ():

(I) ;

(II) ;

(III) , , , ,

T C RMB S . S C S RMB HKD. S HKD S

T B C

Directors, Supervisors and Senior Management

D

E D

M . G A N (管偉立), 53, B D H
C H C F 1996

Directors, Supervisors and Senior Management

Non-Executive Directors

M. QIN H (秦浩), 32, Male, Bachelor's Degree, G J 2021. H (上海正心谷投资管理有限公司), S L V I M C., L J 2017 D 2021.

M. Q P U J 2014, H F U J 2017.

M. LI C (李昌浩), 33, Male, Bachelor's Degree, G O 2021. H SDIC C I F M C., L (國投創益產業基金管理有限公司) J 2022, H SDIC C I F M C., L M 2014 D 2021. H Y A C., L (雲南鋁業股份有限公司), S S E (: 00080 85 T Z 85 T) , , , J 2021.

M. L B U P T , S 2012. H Q M U L D 2013. M. L (CFA) C F A I A 2017, M H R S S P ' R C D 2017, (FRM) G A R P A 2018.

Directors, Supervisors and Senior Management

Independent Non-Executive Directors

M. ZHONG (鍾文堂), 33, Male, Chinese, Bachelor's Degree, G J 2020. S (上海信公企業管理諮詢有限公司), D C C, S I C C., L. (上海信公企業管理諮詢有限公司), F 2019, F 2016 F 2019, M. Z I C C., L., F O 2012 F 2016, P C Z T CPA L C.

M. Z F U S J 2012. S M B A F U J 2022.

M. LI (劉寧), 59, Male, Chinese, Bachelor's Degree, G J 2020. H W H T G C., L. (: 300253.SZ) A 2004, S F 2018, K M T (S) C., L. (快享醫療科技(上海)有限公司), S J 2018, B W H T C., L. (北京衛寧健康科技有限公司), S O 2019, S W T C., L. (上海衛心科技有限公司), F A 1991 A 2004, U S H -P (HP) C (上海金仕達衛寧醫療信息技術有限公司).

M. L F U S J 1985, F U S J 1988, Q R C S P T P S H - A T E S (上海市工程系列高新技術成果轉化類高級專業技術職務任職資格評審委員會) M, 2000.

Supervisors

M. (許寧), 49, Male, Chinese, Bachelor's Degree, S C. H M. X C M 2016, C H M. X M 2016 O 2016, F N 2016 D 2017, H C J 2018 J 2022. H J 2022. H M 2023. P C W TV S (溫州電視台) (《溫州新聞聯播》), S 1998 F 2016,

Directors, Supervisors and Senior Management

M. X. B. B. I. (北京廣播學院) (C. U. C. (中國傳媒大學)) J. 1998, . H. (一級人力資源管理師) M. H. R. S. S. P. R. C. F. 2018.

M. (徐永久), 45, S. . H. C. O. 2021, S. A. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司) S. J. 2021, W. J. E. I. P. (L. P.) (溫州金寧股權投資合夥企業(有限合夥)). S. J. 19, 2018, C. Y. H. C., L. (成都怡寧醫院有限公司). S. F. 2016, S. Y. I. C., L. (上海銀驛投資有限公司). F. J. 2004 D. 2007, D. R. H. S. I. G. . F. D. 2007 Ma. 2009, I. B. H. A. P. C. . F. Ma. 2009 S. 2011, S. I. G. S. I. H. S. T. . F. O. 2011 O. 2015, M. X. GP G. C., L. (金浦產業投資基金管理有限公司). F. A. 2016 Ma. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司).

M. X. S. U. F. E. J. 2000. H. F. U. J. 2004. S. J. 2015, S. L. S. F. U. . H. C. E. I. B. S. EMBA (E. Ma. B. A.) N. 2022.

M. QIAN C. (錢成良), 72, S. . H. . M. Q. C. J. 2017, S. . P. C. Ma. 2007 Ma. 2012,

8

S. S. U. 8.15

1

Directors, Supervisors and Senior Management

S M

M. ZHO C (周朝毅), 60, . H . C M. Z C F 2005 . H . S 2014 C N 1995 D 2004, M. Z W C H (温州心血管醫院) W , . F M 1990 O 1995, M. Z (

Directors, Supervisors and Senior Management

M. (徐誼), 48, . H . C M . X C O 2002 (科長) O 2002 Mar 2009, . F A 2009 S 2014, C H P S 2014 C P

M 5B12190CFB0D8

Directors, Supervisors and Senior Management

M 3 IN H (金輝), 36, . H . P C
H C J 2022 . P C
L (浙江華明會計師事務所有限公司) F 2012 D 2021, C P A C
W ; - ;
M P ' C N 2018, W
. P Z H C P A C L ,
W L C P A C L (溫州立德會計師事務所有限公司)

Directors, Supervisors and Senior Management

Director	Supervisor	Senior Management	Term of Office
WANG L	Y K H	E J	F J 2017
	M C ,L	M	
	Q K H	M	F D 2018
	C ,L		
	B Y H	D	F M 2019
	C ,L		
	H Y N	E J	F D 2020
	S C ,L	G	
	Z F	D	F F 2022
	N T		
	C ,L		
	Z Y H	E J	F S 2022
	T C ,L		
	Z D	C	F S 2022
	P C ,L		
	C K	D	F N 2022
	H		
	H C ,L		

Directors, Supervisors and Senior Management

Director / Supervisor / Senior Management	Position	Gender	Age	Education	Work Experience	Start Year
XU Y	Chairman	Male	58	Master's Degree	1980s	2011
Q K	Director	Male	55	Master's Degree	1980s	2013
Y K	Director	Male	55	Master's Degree	1980s	2013
S Y	Director	Male	55	Master's Degree	1980s	2014
W Y	Director	Male	55	Master's Degree	1980s	2015
B Y	Director	Male	55	Master's Degree	1980s	2015
S Y	Director	Male	55	Master's Degree	1980s	2015
Q Y	Director	Male	55	Master's Degree	1980s	2015
Z H	Director	Male	55	Master's Degree	1980s	2016
T K	Director	Male	55	Master's Degree	1980s	2016
Z K	Director	Male	55	Master's Degree	1980s	2016
H Y	Director	Male	55	Master's Degree	1980s	2017
T L	Director	Male	55	Master's Degree	1980s	2016
H K	Director	Male	55	Master's Degree	1980s	2018
H C	Director	Male	55	Master's Degree	1980s	2017
W T	Director	Male	55	Master's Degree	1980s	2018
W T	Director	Male	55	Master's Degree	1980s	2018
Z J	Director	Male	55	Master's Degree	1980s	2018
T L	Director	Male	55	Master's Degree	1980s	2020
W J	Director	Male	55	Master's Degree	1980s	2021
W Y	Director	Male	55	Master's Degree	1980s	2022

Directors, Supervisors and Senior Management

D  M  G  P  H 

Directors, Supervisors and Senior Management

DIRECTOR	MANAGER	GENERAL MANAGER	DEPUTY GENERAL MANAGER	OTHER
ZHANG F	L K H C., L.	E, M	F J 2018	
	W N P S H C., L.	D	F J 2019	
	L C H C., L.	E, M	F D 2020	
YE M	W Y H T C., L.	E, G	F M 2019 J 2022	
JIN W	Q Y H C., L.	D	F N 2015	
	H Y P H C., L.	D	F D 2018	
	P C Y H C., L.	E	F S 2021	
	G Y N C C., L.	E, G	F M 2021 D 2022	
XUN	G Y H C., L.	E	F J 2019	
	H Y P H C., L.	C	F M 2020	
JIN H	W O Y E H C., L.	S	F S 2022	
	G Y N C C., L.	S	F S 2022	

A

III. K_AMa

K ,



A

A . ,

IV. O I

M. K. H (M)
 . T 2022 K
 H . K H ' 2022 .

O .

I ,

W K H ' 2022 A R ,

V. R M T C G

T M
 CAS ,

I , W K H '
 , , , W K H

T W K H ' .

A . ,

VI. A

C A 31 D 2022 **B** 31 D 2021

A. E	N	V	D 31, 2022		D 31, 2021		J 31, 2021	
			(R)		(R)			
C								
C S P	(I)		271,094,962.97	188,734,845.77	206,499,564.42			
F D N A R A P R P O F I C A N O	(II)		10,641,026.00	10,000,000.00				
	(III)		382,836,690.89	311,757,875.46	225,300,247.01			
	(VI)		32,201,223.97	11,858,427.06	9,909,510.16			
	(V)		37,195,219.68	29,925,487.99	63,465,823.77			
	(VI)		58,331,397.37	56,519,301.23	37,508,471.39			
	(VII)		752,324.77	806,685.85				
			793,052,845.65	609,602,623.36	542,683,616.75			
B								
G D O L L I O I F	(VIII)		14,000,000.00					
	(IX)		143,546,246.10	129,847,779.24	97,816,933.76			
	(X)		63,116,852.05	65,812,274.58	57,404,918.27			
					107,804,936.40			

C 31 D 2022 (A RMB Y)				
LIABILITY AND SHAREHOLDERS' EQUITY				
	N	V	D 31, 2022	D 31, 2021
			(R)	(R)
C : S (XIX) 203,000,000.00 254,050,000.00 312,500,000.00 B				

C

A 31 D 2022

B

LIABILITY AND SHAREHOLDERS' EQUITY	NOTE	December 31, 2022	December 31, 2021	January 1, 2021
			(RMB)	(RMB)
Capital stock:				
State-owned share	(XXXIII)	74,600,300.00	74,600,300.00	74,600,300.00
Other share				
Investment share				
Capital reserve	(XXXIV)	855,078,533.30	838,165,395.59	819,509,065.54
Surplus reserve				23,311,143.84
Undistributed profit	(XXXV)	38,399,577.13	38,399,577.13	36,593,228.71
Minority interest	(XXXVI)	233,506,534.43	257,098,624.31	214,856,099.61
Total		1,201,584,944.86	1,208,263,897.03	1,122,247,550.02
Minority interest		124,317,673.97	72,015,223.54	92,665,008.81
Total		1,325,902,618.83	1,280,279,120.57	1,214,912,558.83
Additional liability and shareholders' equity		2,637,787,406.99	2,377,954,988.76	2,161,261,774.68
Total				

L : P : H :

GUAN W JIN H WANG M

			D. 31,	D. 31,	J. 1,
			2022	2021	2021
38 E	N XVI		(R .)	(R .)	

资产负债表
 截至2022年12月31日
 (人民币元)

资产和负债	截至2022年12月31日	截至2021年12月31日	截至2021年12月31日
所有者权益	(人民币元)	(人民币元)	(人民币元)
流动资产：			
货币资金	195,000,000.00	251,050,000.00	310,000,000.00
应收账款			
预付款项			
其他应收款			
存货			
流动资产合计			
非流动资产：			
长期股权投资	20,689,401.73	13,161,555.37	34,954,083.13
固定资产	3,299,924.90	2,011,708.12	
无形资产			3,480,241.45
递延所得税资产	18,740,841.95	17,876,433.39	15,629,765.62
其他非流动资产	597,972.12	4,848,233.63	8,267,930.79
非流动资产合计	49,473,505.95	74,941,835.88	27,298,927.14
资产总计	91,487,500.00	3,000,000.00	
流动负债：			
应付账款	379,289,146.65	366,889,766.39	399,630,948.13
预收款项			
应付职工薪酬			
应交税费			
其他应付款			
流动负债合计			
非流动负债：			
长期借款	284,750,000.00	200,950,000.00	38,000,000.00
应付债券			
其他非流动负债			
非流动负债合计			
负债合计	25,922,687.47		
所有者权益：			
股本	9,037,891.00	9,341,683.00	9,645,475.00
资本公积	2,291,279.89	2,853,156.89	1,607,648.32
盈余公积			
未分配利润			
所有者权益合计			

LIABILITY AND SHAREHOLDERS' EQUITY		December 31, 2022	December 31, 2021	January 1, 2021
		(RMB)	(RMB)	(RMB)
Non-current assets:				
Long-term equity investments		74,600,300.00	74,600,300.00	74,600,300.00
Other non-current assets				
Prepaid expenses				
Other non-current assets				
Goodwill		871,230,628.64	854,317,490.93	834,138,174.86
Intangible assets				23,311,143.84
Other non-current assets				
Long-term equity investments		38,399,577.13	38,399,577.13	36,593,228.71
Other non-current assets		241,903,691.18	214,974,182.62	198,717,046.87
Total non-current assets		1,226,134,196.95	1,182,291,550.68	1,120,737,606.60
Total non-current liabilities and shareholders' equity		1,927,425,201.96	1,762,326,156.96	1,569,621,678.05

Total non-current liabilities and shareholders' equity

Liu Guanwu: Jin Hui: Han Wang M

CONFIDENTIAL

[illegible]

C
F 2022
(A RMB Y)
I
N V A A
I (R)

附注 2022
(A 人民币 Y)

I		N XVI	A	A
I.				
I.		(IV)	343,141,450.63	369,798,306.12
L : C		(IV)	265,024,147.50	271,489,388.70
T			154,333.60	3,013,304.93
S			1,692,773.94	3,068,742.71
G			82,345,368.26	70,825,757.20
R			18,899,109.47	16,486,961.41
F			16,480,521.45	5,650,976.01
I : I			26,568,676.00	19,722,968.32
I			11,229,395.04	14,521,251.32
A : O			6,245,933.48	5,326,738.38
I	(-)	(V)	49,902,280.65	4,923,377.54
I : I				
			-5,377,605.11	-3,485,811.81
D				
G	(-)			
G	(-)			
			-2,695,422.53	8,407,356.31

P 2022 F (A RMB Y)		C 2022 I (A RMB Y)	
I N XVI		A A	
O		O	
(I) O		O	
1. C		1. C	
2. O		2. O	
3. C		3. C	
4. C		4. C	
(II) O		O	
1. O		1. O	
2. C		2. C	
3. A		3. A	
4. C		4. C	
5. R		5. R	
6. E		6. E	
7. O		O	
I.		26,929,508.56	18,063,484.17
II.E		(I) B (RMB)	
(II) D (RMB)		T	
L :		P : H :	WANG M
GUAN W		JIN H	

C F 2022		C E		
I		N V		A A
I. C				
G				1,452,028,763.13 1,211,114,150.81
N				
N				
N				

C F 2022 (A RMB Y)			
I. N V		A	A
II. C			
G			52,119,175.58
G		1,650,804.41	7,777,189.35
N			
N		24,100,366.61	8,755,311.37
G			
		25,751,171.02	68,651,676.30
G			
G		236,910,178.88	178,536,614.68
N			48,600,000.00
N		53,685,701.28	80,564,032.90
G	(LIV)	8,770,704.43	
		299,366,584.59	307,700,647.58
		-273,615,413.57	-239,048,971.28
III. C			
G		9,153,084.38	2,900,000.00
I			
		9,153,084.38	2,900,000.00
G		387,500,000.00	550,250,000.00
G	(LIV)	151,420,250.00	
		548,073,334.38	553,150,000.00
G			
G		324,220,000.00	428,342,970.00
		51,554,507.56	30,297,107.09
I			
G	(LIV)	56,121,295.37	60,676,565.61
		431,895,802.93	519,316,642.70
		116,177,531.45	33,833,357.30
I. E			
		78,462.87	-38,704.15
		69,861,145.20	-11,357,819.65
A	(LV)	188,734,845.77	200,092,665.42
I. C	(LV)	258,595,990.97	188,734,845.77
T			
L : P : H :			
GUAN W JIN H WANG M			

P C C F S F 2022 (A RMB Y)				
I. N			A	A
I. C				
Ge			336,363,866.37	367,674,455.38
R				
Ge			495,591,067.36	804,490,679.80
			831,954,933.73	1,172,165,135.18
Ge			153,275,777.22	176,137,498.58
Ge			147,419,578.70	141,102,134.39
Pe			2,393,183.16	9,767,527.34
Ge			596,762,811.79	710,127,325.96
			899,851,350.87	1,037,134,486.27
N			-67,896,417.14	135,030,648.91
II. C				
Ge			12,396,717.38	
Ge			2,298,348.18	7,089,189.35
N			32,054.56	37,820.00
N				
Ge				
			14,727,120.12	7,127,009.35
Ge			14,643,564.50	37,662,933.95
Ge			54,309,855.16	212,313,500.00
N				
Ge				
			68,953,419.66	249,976,433.95
N			-54,226,299.54	-242,849,424.60

P F (A			C 2022 RMB Y			C F			N A A		
I.											
III. C											
G											
G									334,500,000.00		
G									120,000,000.00		
									454,500,000.00		
G									306,750,000.00		
G											
									26,512,297.06		
G									6,421,875.00		
									339,684,172.06		
N									114,815,827.94		
I. E											
									78,462.87		
N									-7,228,425.87		
A : C									97,615,570.76		
I. C									90,387,144.89		
T											
L											
GUAN W											
P											
JIN H											
H											
WANG M											

C									
F									
(A									
2022									
RMB Y									
)									
C									
O									
'E									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									

C		C		O		'E	
F		2022					
(A		RMB Y					

C F (A									
2022									
RMB Y									
(									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									
)									

2022
(A) RMB Y

I		O		A		O		S		S		R		T	
P		P		P		P		P		P		P		P	
S		S		S		S		S		S		S		S	
74,600,300.00		834,138,174.86		23,311,143.84		36,593,228.71		193,286,602.86		1,115,307,162.59		5,430,444.01		5,430,444.01	
I. B		834,138,174.86		23,311,143.84		36,593,228.71		193,286,602.86		1,115,307,162.59		5,430,444.01		5,430,444.01	
II. B		834,138,174.86		23,311,143.84		36,593,228.71		193,286,602.86		1,115,307,162.59		5,430,444.01		5,430,444.01	
III. I		20,179,316.07		-23,311,143.84		1,806,348.42		16,257,135.75		61,533,944.08		18,063,484.17		20,182,750.66	
(I) T		20,182,750.66		2,445,056.34		17,737,694.32		-1,806,348.42		-1,806,348.42		-1,806,348.42		-1,806,348.42	
(II) O		2,445,056.34		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68	
1. C		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
2. C		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68		1,182,291,550.68	
3. S		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
4. C		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68		1,182,291,550.68	
5. C		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
6. O		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68		1,182,291,550.68	
(VI) S		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
1. W		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
2. U		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68		1,182,291,550.68	
(VII) O		17,737,694.32		-3,434.59		-23,311,143.84		38,399,577.13		214,974,182.62		1,182,291,550.68		1,182,291,550.68	
I. B		834,138,174.86		23,311,143.84		36,593,228.71		193,286,602.86		1,115,307,162.59		5,430,444.01		5,430,444.01	

T :
L :
GUAN W
JIN H
WANG M

NE
F 2022
(A RMB Y)

I. G

(I) C

W K H C ., L . (C)
W C K P R H (溫州市康寧精神康復醫院)
PRC F 1996. T C

NEF 2022
(A RMB Y)

II. B

(I) B

T A S B E -
B S A S
B E , A S B E
M F (A S
B E). I ,
R G L S T S E H K L
H K C O .

(II) G

T .

III. S

1. T C
C
2. F
C
C
3. T C
P . T
C

NE
F 2022
(A RMB Y)

III. S ()

(I) A B E
T A S B E
M F , 31, 2022 2022.
C D

(II) A
T C 1 J 31 D .

(III) O
T C 12 .

(I)
T C R (RMB) T C
C PRC RMB. T
RMB.

() A
B : T ,
(T
() . I
, ,


III. S

() A ()

B
: T
W
C
;
T
.

T

(I) P

1. S 

F
 (A

2022
 RMB Y

F
 J

III. S

(I) P ()

2. C ()

T

(1) I

D R P , C ,

R P ;

[illegible]

N	F	E	J	J	J	J	J	J
F	2022	RMB Y						
(A								
III. S								
(I) P								
2. C								
(1) I								
W								
C								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								
W								



NE
F 2022 F
(A RMB Y)



NE
F 2022 F
(A RMB Y)

N
 F
 (A 2022 RMB Y)
 III. S ()
 () F ()
 1. C ()

W
F
(A)

2022
RMB Y)

E
J

2022 年 12 月 31 日止，公司净资产为 10,000.00 万元，较年初增加 1,000.00 万元，增幅为 11.11%。

III. S 公司净资产变动情况如下表所示：

() F 公司净资产变动情况如下表所示：

2. R 公司净资产变动情况如下表所示：

(3) F 公司净资产变动情况如下表所示：

F 公司净资产变动情况如下表所示：

2022 年 12 月 31 日止，公司净资产为 10,000.00 万元，较年初增加 1,000.00 万元，增幅为 11.11%。

A 公司净资产变动情况如下表所示：

NEF 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(6) F

F - , ,
 , - ,
 , ,
 .

D ,

A ,

3. D

W , C :

— T ;

— T , ;

— T , C

A ,

I ,

N
 F
 (A
 2022
 RMB Y
 III. S
 (

N F
 F 2022
 (A RMB Y)

III. S $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ ()

() F ()

4. D  ()

W


$$W = \begin{pmatrix} \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \end{pmatrix}, \quad \begin{pmatrix} \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \end{pmatrix} \left(\begin{pmatrix} \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \end{pmatrix} - \begin{pmatrix} \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} & \frac{1}{2} & \frac{1}{2} \end{pmatrix} \right).$$
[illegible]

5. D

T
T
. T
. I , C
U

6. T

T C 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

G)  , C   .

NE
F 2022
(A RMB Y)

III. S ()

() F ()

6. T ()

I
C ;
C 12-
.T

I
C
30 C
U
30 C

I C

I - C

F A S
B E N .14 - R (2017),
C

W
F
(A)

2022
RMB Y)

E
J

NE
F 2022
(A RMB Y)

III. S ()

(I)I

1. C
I
I
C
2. V
I
3. B
A
N
N

NE
F 2022
(A RMB Y)

III. S ()

(I) I ()

4. I
A

5. A
T -

(II) C

1. R
T C . T C
. C
. T C
()

2. D
F
3



2022
 RMB Y ()
 III. S ()
 (III) L - ()
 2. D

F
 (A

2022
 RMB Y

F
 J

)

III. S

(III) L - ()

3. S $\begin{smallmatrix} \rightarrow & \rightarrow \\ \rightarrow & \rightarrow \end{smallmatrix}$


(1) $L = \frac{1}{2} \int_{-\infty}^{\infty} \left(\frac{1}{2} \left(\frac{d\psi}{dx} \right)^2 + \psi^2 \right) dx$

(2) L - 1

L - , W , G , , W , G , ,

T C O C O , E) , . T . I ,

T C , O C
O E C
C

F 2022
 (A RMB Y)

III. S ()

(III) L - ()

3. S ()

(2) L - ()

U C C ,
 C ,
 . U ,
 ,

T C -
 C -
 C C () 0.018 GS0 0.. W 0.5 (8 T

N	F	2022	F	J	J	J	J	J	J	J	J	J	J	J	J	J
F	F	RMB Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
(A	A	)	)	)	)	)	)	)	)	)	)	)	)	)	)	)
III. S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
(III) L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L
3. S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
(3) D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W	W
G	G	G	G	G	G	G	G									

NEF 2022
(A RMB Y)

III. S ()

(I) F

1. R
F
, A

(1) ;

(2) .

T () .

S
G
. T . A

2. D
F
T
F
W
W

N F
 F 2022
 (A RMB Y)

III. S

(I) F (.)

2. $D \rightarrow D$ ()

T , , :

C		D ₁ (€)	D ₂ (€)	A	
				Duration (years)	Yield (%)
B	☹	S ☹ -	35	5	2.71
M	☹	S ☹ -	3-10	0-5	9.50-33.33
M	☹	S ☹ -	4-10	5	9.50-23.75
E	☹	S ☹ -	3-10	0-5	9.50-33.33

3. D 

A $\mathcal{P}_i$ $\mathcal{T}$ $\mathcal{P}_j$, $\mathcal{P}_k$, $\mathcal{P}_l$, $\mathcal{P}_m$, $\mathcal{P}_n$, $\mathcal{P}_o$, $\mathcal{P}_p$, $\mathcal{P}_q$, $\mathcal{P}_r$, $\mathcal{P}_s$, $\mathcal{P}_t$, $\mathcal{P}_u$, $\mathcal{P}_v$, $\mathcal{P}_w$, $\mathcal{P}_x$, $\mathcal{P}_y$, $\mathcal{P}_z$.

(4) C

C

, A

. C

.

NE F
(A 2022 RMB Y)

III. S ()

(I) B

1. R
T C
;

A
;

2. G
G
;

G

(1) A
;

(2) B
;

(3) T
.

G
.

3. G

I
;
3
;
B
.

NEF 2022
(A RMB Y)

III. S ()

(I) B ()

4. M
F
F
D

(II) I

1. V
(1) I
T
(2) S
T C
A
,

III. S

(II) I ()

2. $E \rightarrow E \rightarrow E$

E

I	()	A	B
L	40-50	S -	S
S	5	S -	E
C	20-30	S -	E
M	5-20	S -	E
T	10	S -	E

3. S

R

R

D\ : D\ \

NE
F 2022
(A RMB Y)

III. S ()

(II) I ()

4. C
T
T
:
 - (1) I ;
 - (2) T C ;
 - (3) T , ,
 ,
 ,
 - (4) T C , , ,
 , , ,
 - (5) T , , , , ,
- I , ,

(III) I ,

L - , - , , - - ,
 , I
 ,
 , T , P
 , I
 , A

III. S $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ ()


(Ⅲ) I — ()

G

W C , C , T

O    ,  .

(I) L -

L - 

() C L

NE
F 2022
(A RMB Y)

III. S ()

(I) E

1. A -
T -

W C

W C .N -

2. A -

(1) C

T C .D
, C
.I , C
/
.T C /
.C

NEF 2022
(A RMB Y)

III. S ()

(I) E ()

2. A - ()

(2) D

T C E A W U M .T

T , .I , C

A ,

T .C .U

U ,

3. A W C () : C ; C

N		F	
F		2022	
(A		RMB Y	
III. S		(	
(II) P			
T C			
(1)		C	
(2)		C	
(3)			
A			
Fe			
W			

N		E	
F (A	2022 RMB Y		
III. S			()
(			
A	-	C	C
1. E			
T			
C			
I			
I			

NEF 2022
(A RMB Y)

III. S ()

()

2. G - - - - -
A - - - - - C F - - - - -
- - - - - , - - - - -
- - - - - , - - - - -
- - - - - F - - - - -
- - - - - , - - - - -
- - - - - , - - - - -
- - - - - C - - - - -
- - - - - . F - - - - -
- - - - - , - - - - -

I C - - - - -
- - - - - O - - - - -
- - - - -), C - - - - -
- - - - - . A - - - - -
- - - - - , - - - - -
- - - - - . I - - - - -
- - - - - , C - - - - -

(I)

1. A - - - - -
T C - - - - -
- - - - - . C - - - - -
- - - - - , - - - - -

I - - - - -
C - - - - -
- - - - -
- - - - - , - - - - -
- - - - -

NE
F 2022
(A RMB Y)

III. S ()

(I) ()

1. A ()

T C
 ,
 . T C
 . W
 , C
 ,
 . T C
 . W
 , C
 . T
 .

W , C
 . O , C
 :

- A C , C
- T C
- G C . I , C

W ,
 T C
 . W
 , C

III. S (A) 2022 RMB Y)

(I) ()

1. A ()

F , C , I

C :

• C , ,

NE
F 2022
(A RMB Y)

III. S ()

() C ()

I C ,

A ; ,

F , C

1. T ;

2. T

I - ,

() G

1. T

G - C

G C ,

2. T

G C

F
(A

III. S

I) G

3. A

A - . T

(C

G C

C

D

I C

D F

NE
F 2022 F
(A RMB Y)

NE
F 2022
(A RMB Y)

III. S ()

(III)D ()

A ,

- W ;
- W

(III)L

A , , A , C , A , , ()

F , C F - ,

I COVID-19 , C - ;

- T ;
- A

N F 2022 F
 (A RMB Y)

III. S ()

(III) L ()

1. T C

(1) R - -

A , C - -
 (S -). R - -
 . S :

-
-
-
-
-

T C - . I
 , C
 C
 .

T C - -
 N III. (XVIII) I -

NEF 2022
(A 2022 RMB Y 100,000,000)

III. S 100,000,000 (100,000,000)

(III) L 100,000,000

1. T C 100,000,000 (100,000,000)

(2) L 100,000,000

A 100,000,000, C 100,000,000 (100,000,000) - 100,000,000 (100,000,000). L 100,000,000 (100,000,000) 100,000,000 (100,000,000). L 100,000,000 (100,000,000) :

- 100,000,000 (100,000,000) - 100,000,000 (100,000,000), 100,000,000 (100,000,000) 100,000,000 (100,000,000);

- 100,000,000 (100,000,000) 100,000,000 (100,000,000);

- 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000) C 100,000,000 (100,000,000)

- 100,000,000 (100,000,000) 100,000,000 (100,000,000) C 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000);

- 100,000,000 (100,000,000) 100,000,000 (100,000,000), 100,000,000 (100,000,000) C 100,000,000 (100,000,000) 100,000,000 (100,000,000).

T C 100,000,000 (100,000,000) 100,000,000 (100,000,000). I 100,000,000 (100,000,000) 100,000,000 (100,000,000) C 100,000,000 (100,000,000).

T C 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000).

Va 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000) 100,000,000 (100,000,000).

NE F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(2) L ()

A , C I
- -
- -
C

• ,
C
;

• - ,
C .H ,

(3) S -

T - C -
- -

S - 12

. L
. W C

NEF 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(4) L

T C :
:

- ;

- .

I , C , - ,
V .

I , C ,
- - , F
C , C
- -

(5) R COVID-19

F COVID-19 , C ,
 ,
 , I ,
 , C , W
 ,
 - ,
 , C

N		F		E											
F	(A	2022	RMB Y												
III. S															
(	III	L													
1.	T	C													
(5)	R					COVID-19									
F	-														
2.	T	C													
A															

N F (A	2022		F			
	2022	RMB Y	2022	RMB Y	2022	RMB Y
III. S						
(III)						

N	F	E						
F (A	2022 RMB Y							
III. S						(		)
(	III) L		(					)
2.	T C		(					)
(3)	R			COVID-19				

NE
F 2022
(A RMB Y)

III. S ()

(III) L ()

3. S ()

(2) T C

I - C
2. T
C ; -
C ,
F
N III (X) F

(I)

T C ,

A C : (1)
; (2)
C
(3)
C T

()

T C ,

1. E

A N III. (XXIV), C
T

NEF
F (A 2022
(A 2022 RMB Y)

III. S ()

()

2. E

A N III. (XVIII), C
T
(N V. (XV))

I EBIT
EBIT
C

3. E

T
C
()

4. M

I 2022, C
H Y H C., L
;

I E P

A ()	180
A (/)	570
N	10.79%
G (/)	60
D	14.00%
P	2.50%

NE
F (A 2022 RMB Y)
III. S ()
(I) C
I 2021, M F N P D I E
A S N . 15 I 2022 2023, M F N P
D I E A S N . 16 Q&A I
E A S . T C 31
D 2022 -
Q&A. T C

IV. T

(I) M		
V (VAT)	T VAT	3%, 6%, 13%
U B VAT		7%
E B VAT		5%
E B		15%, 20%, 25%
C		
W K H C ., L .		15%
Z J H T C ., L .		15%
Y K H M C ., L .		20%

NE
F 2022
(A RMB Y)

IV. T ()

(II) P

1. P C O P P
L VAT P B T (C S [2016] N . 36) M F
S T A , C
A M M I (O S C N . 149)
S C I M A M I
(O M H N . 35) M H

I		B		B	
C		C		C	
2022	2022	2022	2022	2022	2022
(A)	(A)	(A)	(A)	(A)	(A)
V. N	V. N	V. N	V. N	V. N	V. N
(I)	(I)	(I)	(I)	(I)	(I)
454,907.26		454,907.26		971,773.72	

N		F	
F		2022	
(A		RMB Y	
V. N		(	
(III) A			
1. A		B	
A		B	
W 1		388,961,193.05	303,910,574.15
1-2		4,755,919.87	9,812,859.20
2-3		3,941,367.25	4,259,870.27
O 3		5,180,894.08	3,140,407.07
S -		402,839,374.25	321,123,710.69
L : P		20,002,683.36	9,365,835.23
T		382,836,690.89	311,757,875.46
T		C	
. T			

NEF 2022
(A 2022 RMB Y)

V. N ()

(III) A ()

2. A	B	B	P	B	P	P	P	P	P	P	P
C	A	(%)	A	(%)	B	A	(%)	A	(%)	B	
P											
	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	2.26	4,590,286.39	63.33	2,657,692.22	
I											
M	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	50.00	4,590,286.39	63.33	2,657,692.22	
P											
	384,617,398.37	95.48	7,488,540.70								

---	--	--	--	--

N F
 F 2022
 (A RMB Y)

V. N. ()

(III) A $\mathbb{Z}$ -module M is *free* if $M \cong \bigoplus_{i \in I} \mathbb{Z}$ for some set I .

3. $P \rightarrow Q$ is true, P is true, Q is true. $P \rightarrow Q$ is true, P is false, Q is true. $P \rightarrow Q$ is true, P is false, Q is false. $P \rightarrow Q$ is false, P is true, Q is false. $P \rightarrow Q$ is false, P is false, Q is false.

P					
P					
T					

4. A $\frac{1}{2}$ $\frac{1}{2}$ A -

A $\frac{1}{2}$ $\frac{1}{2}$ 365,374.61

NEF 2022
(A 2022 RMB Y)

V. N ()

(I) A

1. A

A	B			B		
	A	P	(%)	A	P	(%)
W 1	29,973,748.69		93.08	11,751,451.87		99.11
1-2	2,127,484.58		6.61	58,511.20		0.49
2-3	56,690.70		0.18	24,163.99		0.20
Q 3	43,300.00		0.13	24,300.00		0.20
T	32,201,223.97		100.00	11,858,427.06		100.00

NEF 2022
(A RMB Y)

V. N ()

() O

	B	B
I		
I		
D		
O	37,195,219.68	29,925,487.99
T	37,195,219.68	29,925,487.99

(1) O

	B	B
A		
W 1	31,752,956.09	20,470,501.76
1 - 2	12,384,779.19	4,096,700.18
2 - 3	4,035,447.86	838,693.49
3 - 4	1,755,508.40	2,814,221.11
4 - 5	101,363.87	1,452,266.68
O 5	3,877,306.68	2,930,000.00
S	53,907,362.09	32,602,383.22
L : P	16,712,142.41	2,676,895.23
T	37,195,219.68	29,925,487.99

附注五、非经常性损益明细表
 2022年度
 (A 币种: 人民币)

五、非经常性损益明细表 (单位: 元)

(一) 营业外收入 (单位: 元)

(2) 营业外收入 (单位: 元)

C 项目	B 年初余额		B 本年年末余额		B 年初余额		B 本年年末余额		B 年初余额		B 本年年末余额	
	A 年初余额	(%)	A 本年年末余额	(%)	A 年初余额	(%)	A 本年年末余额	(%)	A 年初余额	(%)	A 本年年末余额	(%)
P 营业外收入												
1 政府补助	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29	4.40	1,435,560.00	4.40	1,435,560.00	100.00		
I 合计:												
H 合计												
U 营业外收入												
C 营业外收入												
A 营业外收入, P 营业外收入												
C 营业外收入							1,435,560.00	100.00	1,435,560.00	100.00		
H 营业外收入												
C, L 营业外收入	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29							
P 营业外收入												
1 政府补助	28,569,342.89	53.00	860,111.50	3.01	27,709,431.39	95.60	31,166,823.22	95.60	1,241,335.23	3.98	29,925,487.99	
I 合计:												
P 营业外收入	28,569,342.89	53.00	860,111.50	3.01	27,709,431.39	95.60	31,166,823.22	95.60	1,241,335.23	3.98	29,925,487.99	
T 合计	53,907,362.09	100.00	16,712,142.41	37.19	37,195,219.68	32.60	32,602,383.22	100.00	2,676,895.23		29,925,487.99	

N F F 2022 RMB Y)			
V. N ()			
() O ()			
(2) O ()			
P V :			
B P P			
N	B	(%)	
H Y H C.,L . 25,337,819.20 15,852,030.91 62.56			
T	25,337,819.20	15,852,030.91	
D P V : P N III. (X)			
P V :			
B P P			
N	O	(%)	
P	28,569,542.89	860,111.50	3.01
T	28,569,542.89	860,111.50	
C P V : P			
N III. (X)			

NEF 2022
(A RMB Y)

V. N ()

() O ()

(3) D

	1	2	3
		L	
		ECL	L
12-	(-	ECL (-	
P ECL			
B 2	1,241,335.23	1,435,560.00	2,676,895.23
B 3			
Y /			
-T 2			
-T 3			
-R 2			
-R 1			
P	141,793.04	15,852,030.91	15,993,823.95
R	485,492.80	1,435,560.00	1,921,052.80
W	37,523.97		37,523.97
W			
O			
B	860,111.50	15,852,030.91	16,712,142.41

附注 12 递延所得税资产和递延所得税负债 截至 2022 年 12 月 31 日止年度 (A 币种为人民币元)			
V. 非流动资产			
(一) 递延所得税资产			
(3) 递延所得税资产			
C 币种为人民币元			
	截至 2022 年 12 月 31 日止年度 递延所得税资产	截至 2021 年 12 月 31 日止年度 递延所得税资产	截至 2020 年 12 月 31 日止年度 递延所得税资产
B 币种为人民币元	12- ECL	12- ECL	12- ECL
递延所得税资产	31,166,823.22	1,435,560.00	32,602,383.22
递延所得税资产			
递延所得税资产			
-T 币种为人民币元	2		
-T 币种为人民币元	3		
-R 币种为人民币元	2		
-R 币种为人民币元	1		
A	2,428,909.82	25,337,819.20	27,766,729.02
D	4,306,570.80	1,435,560.00	5,742,130.80
O 币种为人民币元	-719,619.35		-719,619.35
B 币种为人民币元	28,569,542.89	25,337,819.20	53,907,362.09

N F (A 2022 RMB Y)					
V. N ()					
() O ()					
(4) P ,					
B C R W B					
C					
P	1,435,560.00	15,852,030.91	1,435,560.00		15,852,030.91
P	1,241,335.23	141,793.04	485,492.80	37,523.97	860,111.50
T	2,676,895.23	15,993,823.95	1,921,052.80	37,523.97	16,712,142.41
O ,					
D					
N					
H U C	1,435,560.00	F	R	M	
C D					
A T , P C					
T	1,435,560.00				

N F 2022 F (A RMB Y)		
V. N	()	
() O	()	
(5) O		
I	A	-
O		37,523.97
(6) O		
	B	B
N		
D	20,677,631.31	23,577,997.61
P	816,666.30	4,228,330.66

NEF 2022
(A RMB Y)

V. N ()

(I) I

I	B			
	P			
T	3,697,607.74	3,697,607.74	2,242,027.51	2,242,027.51
C	54,633,789.63	54,633,789.63	54,277,273.72	54,277,273.72
T	58,331,397.37	58,331,397.37	56,519,301.23	56,519,301.23

(II) O

I	B	
	P	
I	196,008.48	137,228.50
P	269,072.88	321,191.35
P	287,243.41	348,266.00
T	752,324.77	806,685.85

NEF 2022
(A RMB Y)

V. N ()

(III) L

B		B		P		D	
I	B	B	B	P	B		
E	14,000,000.00	14,000,000.00					
T	14,000,000.00	14,000,000.00					

(I) L -

I		I		I		I		I	
I	I	I	I	I	I	I	I	I	I
A									
M	13,156,356.09	-4,287,437.64	5,310,451.69					14,179,350.14	
W									
Y	58,100,000.00	500,000.00						57,600,000.00	
Z									
H	22,193,790.14	-1,090,147.47						21,103,642.67	
S									
M	23,198,356.89	-1,102,416.10						22,095,940.79	
C									
K	18,687,211.65	74,969.38	400,000.00					18,362,181.03	
C	11,514,784.92	-1,309,633.45						10,205,151.47	
J	5,191,069.69						5,191,069.69		
H									
(N)									
T	129,847,779.24	22,193,790.14	500,000.00	-7,714,705.28	5,310,451.69	400,000.00	5,191,069.69	143,546,246.10	

N : O 10 A 2022, Z K H M (G) C , L . (Z K), C 28% H Y H C , L . (H Y), , T W L L Y H M C , L . (L L) RMB14,000,000.00, S A C J H G S I I E I F P (L.P.), C J P II M H S I I E I F P (L.P.), T W L L Y H M C , L . , L L , RMB13,922,929.38 , Z K , H Y 33% . U Y B , H Y RMB8,212,142.17 C Y H

NE
F 2022
(A RMB Y)

V. N ()

() O

B B

I		
F	63,116,852.05	65,812,274.58
I : I	63,116,852.05	65,812,274.58
T	63,116,852.05	65,812,274.58

V. N		()		()		F		F	
(D F)		()		()		2022		2021	
2. D		()		()		RMB Y		RMB Y	
I		B		M		E		F	
1. O		745,833,959.90		142,218,120.78		6,548,724.87		68,038,620.62	
(1) B		811,977.80		25,247,491.51		6,016,909.41		9,508,145.59	
(2) I		811,977.80		14,854,645.52		2,906,555.91		5,748,234.46	
-P									
-T									
-I				10,392,845.99		3,110,353.50		3,759,911.13	
-O								140,027,233.85	
(3) D		70,270,990.67		65,654,865.68		3,162,440.49		25,386,159.55	
-D				12,438,192.49		658,984.47		3,310,725.18	
-D				5,259,711.00		565,764.12		2,213,845.28	
-O		70,270,990.67		47,956,962.19		1,937,691.90		19,861,589.09	
(4) B		676,374,947.03		101,810,746.61		9,403,193.79		52,160,606.66	
								140,027,233.85	
								979,776,727.94	

V. N		(I) F		2022		RMB Y	
2.	D	(	)	B	M	E	F
2. A	(1) B	6		97,583,529.57	93,448,930.55	2,620,876.20	47,139,318.33
	(2) I			21,780,272.36	23,765,333.80	3,918,211.31	9,282,744.01
	-P			21,780,272.36	21,259,481.17	1,035,359.81	8,378,127.80
	-I				2,505,852.63	2,882,851.50	904,616.21
	-O						
	(3) D			12,029,010.56	48,647,077.77	1,557,788.21	19,170,037.34
	-D				6,650,418.76	620,766.50	1,300,387.75
	-D			1,654,288.20	3,475,806.87	214,904.65	1,442,900.18
	-O			10,374,722.36	38,520,852.14	722,117.06	16,426,749.41
	(4) B	6		107,334,791.37	68,567,186.58	4,981,299.30	37,252,025.00
3. I	(1) B	6					
	(2) I						
	(3) D						
	(4) B	6					
4. C	(1) C	6		569,040,155.66	33,243,560.03	4,421,894.49	14,908,581.66
	(2) C	6		648,250,430.33	48,769,190.23	3,927,848.67	20,899,302.29

附注五、非经常性损益明细表
 2022年度
 (A 币种: 人民币)

五、非经常性损益明细表 (单位: 元)

(二) 其他非经常性损益

1. 其他非经常性损益明细表

项目	本期发生额	上期发生额
非流动资产处置损益		
计入当期损益的政府补助		
除上述各项之外的其他营业外收入和支出		
其他非经常性损益		
合计	152,497,399.68	43,795,718.15
合计	152,497,399.68	43,795,718.15

2. 其他非经常性损益

项目	本期发生额	上期发生额	本期发生额	上期发生额
非流动资产处置损益				
计入当期损益的政府补助				
除上述各项之外的其他营业外收入和支出				
其他非经常性损益				
合计	152,497,399.68	43,795,718.15	43,795,718.15	43,795,718.15

V. N ()

(III)C ()

3. M

2022 RMB Y

F

I : C, I

	B	I	D	B	P	A	I	I : C, I
P	MB'0,000	(%)	(%)	(%)	(%)	(%)	(%)	(%)

T								
L Y H	18,003.00	6,213,670.10	66,247,515.67	72,461,185.77	40.25	40.00	1,883,479.17	1,608,608.70
T								4.90
P C H	1,897.75	7,504,860.00	17,107,073.00	24,611,933.00	100.00	100.00		0
T								
O Y H	4,047.80	27,288,038.64	11,021,933.76	38,310,012.40	100.00	100.00		0
T								
L C								
H	16,020.00	150,609.00	27,385,840.81	27,536,449.81	17.19	20.00		0
T								
Q Y								
H	9,848.00		16,073,697.42	16,073,697.42	16.32	15.00		0
T								
J								
H	6,666.00		35,508,167.99	35,508,167.99	54.15	55.00		0
T								
		41,157,197.74	173,344,248.65	62,921,945.40	151,579,500.99		1,883,479.17	1,608,608.70

附注五、非经常性损益明细表
 2022年度
 (A 币种:人民币)

五、非经常性损益明细表 (单位:元)

(III) 非经常性损益明细表

I. 非经常性损益明细表		B. 非经常性损益明细表	
1. 营业外收入			
(1) 营业外收入	363,270,419.51	363,270,419.51	
(2) 营业外支出	37,254,480.17	37,254,480.17	
- 营业外收入	21,847,297.56	21,847,297.56	
- 营业外支出	15,407,182.61	15,407,182.61	
(3) 营业外收入	81,876,743.78	81,876,743.78	
- 营业外收入	16,772,968.78	16,772,968.78	
- 营业外支出	65,103,775.00	65,103,775.00	
(4) 营业外收入	318,648,155.90	318,648,155.90	
2. 营业外支出			
(1) 营业外支出	105,858,149.38	105,858,149.38	
(2) 营业外收入	38,189,335.84	38,189,335.84	
- 营业外收入	38,189,335.84	38,189,335.84	
(3) 营业外支出	15,803,080.90	15,803,080.90	
- 营业外支出	4,949,246.94	4,949,246.94	
- 营业外收入	10,853,833.96	10,853,833.96	
(4) 营业外支出	128,244,404.32	128,244,404.32	
3. 营业外收入			
(1) 营业外收入			
(2) 营业外支出			
(3) 营业外收入			
(4) 营业外支出			
4. 营业外收入			
(1) 营业外收入	190,403,751.58	190,403,751.58	
(2) 营业外支出	257,412,270.13	257,412,270.13	

NE
F (A 2022 RMB Y)

V. N ()

(I) I

C

		L		M			
I							
1.O							
(1)		102,977,820.17	3,061,637.13	14,252,889.08	129,837,000.00	32,400,000.00	282,529,346.38
(2)		25,616,355.88		-3,433,306.28	29,000,000.00		51,183,049.60
-P		19,841,690.88		-4,460,006.28			15,381,684.60
-I		5,774,665.00		1,026,700.00	29,000,000.00		35,801,365.00
(3)				1,141,970.00			1,141,970.00
-D				508,000.00			508,000.00
-D				633,970.00			633,970.00
(4)		128,594,176.05	3,061,637.13	9,677,612.80	158,837,000.00	32,400,000.00	332,570,425.98
2.A							
(1)		9,610,253.66	360,120.18	9,441,245.79	27,772,369.86	7,353,571.43	54,537,560.92
(2)		2,889,207.41	330,465.48	1,799,113.48	17,315,075.42	1,500,000.00	23,833,861.79
-P		2,889,207.41	330,465.48	1,072,248.57	17,315,075.42	1,500,000.00	23,106,996.88
-I				726,864.91			726,864.91
(3)				485,345.23			485,345.23
-D				39,066.67			39,066.67
-D				446,278.56			446,278.56
(4)		12,499,461.07	690,585.66	10,755,014.04	45,087,445.28	8,853,571.43	77,886,077.48
3.I							
(1)							
(2)							
(3)							
(4)							
4.C							
(1)		116,094,714.98	2,371,051.47	-1,077,401.24	113,749,554.72	23,546,428.57	254,684,348.50
(2)		93,367,566.51	2,701,516.95	4,811,643.29	102,064,630.14	25,046,428.57	227,991,785.46

2022
RMB Y (A)

B

D

I

B

(

(

V. N
() G
1. C

NEF 2022
(A RMB Y)

V. N ()

() G ()

2. I

A C ;

U : RMB'0,000

A 31 D 2022

N Y H C.,L .	927.18
H Y P H C.,L .	69.03
G Y H C.,L .	154.90
W N P S H C.,L .	778.49
B Y H C.,L .	2,298.73
W Y H T C.,L .	15.11
H K H C.,L .	506.9
C K P H C.,L .	684.33
W C H C.,L .	1,941.63
P C Y H C.,L .	5,177.02
H Y N S C.,L .	127.26
Z F N T C.,L .	32.60
J S H C.,L .	506.03

T 13,219.21

I , C () . I

N F
 F 2022
 (A RMB Y)

V. N. ()

(4) G is a $\mathbb{Z}$ -module.

3. P $\rightarrow$ Q , $R \rightarrow Q$ $\vdash$ $R \rightarrow P$

A

A

p

N

p -

A

$$\left(\begin{array}{cc} & \\ & \end{array} \right)$$

N ₁ Y H C ₁ ,L ₁	219	337	2.50%	21.33%	14.00%
H Y P ₁ H C ₁ ,L ₁	267	289	2.50%	20.60%	14.00%
G ₁ Y H C ₁ ,L ₁					
W N ₁ P ₁ S ₁ H ₁					
C ₁ ,L ₁	323	291	2.50%	22.06%	14.00%
B Y H C ₁ ,L ₁	32	1,810	2.50%	-2.40%	14.00%
W Y ₁ H ₁ T ₁ C ₁ ,L ₁					
H ₁ K ₁ H C ₁ ,L ₁	211	196	2.50%	16.94%	14.00%
C ₁ K ₁ P ₁ H ₁					
C ₁ ,L ₁	315	205	2.50%	17.48%	14.00%
W C H C ₁ ,L ₁	325	546	2.50%	9.59%	14.00%
C ₁ K ₁ H ₁ H C ₁ ,L ₁	213	400	2.50%	19.01%	14.00%
P ₁ C ₁ Y H C ₁ ,L ₁	425	594	2.50%	6.71%	14.00%
P ₁ Y H ₁ H C ₁ ,L ₁	270	273	2.50%	15.82%	14.00%
H ₁ Y N ₁ S ₁ C ₁ ,L ₁	72	117	2.50%	21.92%	14.00%
J ₁ S ₁ H C ₁ ,L ₁	382	284	2.50%	22.65%	14.00%

O   :

A) ;

NEF 2022
(A RMB Y)

V. N ()

() G ()

4. I

I 2022, COVID-19, B Y H C., L . D , C , RMB10,345,460.56 .

(I) L -

B

A

B

I

O

I

R	150,328,412.40	100,049,601.67	46,186,845.31	14,777,100.83	189,414,067.93
L	172,625.00	94,613.90	94,967.96		172,270.94
T	150,501,037.40	100,144,215.57	46,281,813.27	14,777,100.83	189,586,338.87

(II) D

1. D

B

B

D

D

D

D

I

P	16,979,155.87	3,164,380.59	8,026,079.93	1,687,621.09
U				
D	50,169,236.15	8,217,114.53	18,012,806.84	4,503,201.71
D	4,390,510.38	1,097,627.60	4,653,187.96	1,163,296.99
S	54,688,502.33	8,203,275.35	46,552,302.33	6,982,845.35
T	126,227,404.73	20,682,398.07	77,244,377.06	14,336,965.14

NEF 2022
(A 2022 RMB Y)

V. N ()

(II) D ()

2. D

	B	B	T	D
I				
A				
	148,564,631.76	37,141,157.94	144,340,394.12	36,085,098.53
C	13,116,852.07	1,967,527.81	15,812,274.60	2,371,841.19
O	6,620,111.12	1,439,193.06	6,958,909.45	1,418,850.23
T	168,301,594.95	40,547,878.81	167,111,578.17	39,875,789.95

(III) O

	B	P	C	B	P	G
I	B			B		
P	6,936,000.00		6,936,000.00	6,936,000.00		6,936,000.00
P	6,605,047.21		6,605,047.21	130,386.60		130,386.60
T				14,000,000.00		14,000,000.00
T	13,541,047.21		13,541,047.21	21,066,386.60		21,066,386.60

(I) -

	B	B
I		
S	195,000,000.00	200,000,000.00
G	8,000,000.00	54,050,000.00
T	203,000,000.00	254,050,000.00

附注五、非经常性损益明细表
 2022年度
 (A 币种: 人民币 Y 币种: 人民币)

V. 非流动资产处置损益 ()

() 非流动资产处置损益

项目	本期金额	上期金额
处置固定资产、无形资产和其他长期资产产生的损益		
处置长期股权投资产生的损益		
处置其他非流动资产产生的损益		
非流动资产处置损益合计	13,922,929.38	13,922,929.38
非流动资产处置损益合计	13,922,929.38	13,922,929.38

(I) 非流动资产处置损益

项目	本期金额	上期金额
处置固定资产、无形资产和其他长期资产产生的损益		
处置长期股权投资产生的损益		
处置其他非流动资产产生的损益		
非流动资产处置损益合计	997,944.00	
非流动资产处置损益合计	997,944.00	

(II) 其他非流动资产处置损益

项目	本期金额	上期金额
处置固定资产、无形资产和其他长期资产产生的损益		
处置长期股权投资产生的损益		
处置其他非流动资产产生的损益		
非流动资产处置损益合计	84,193,738.77	55,761,620.69
非流动资产处置损益合计	1,161,389.02	2,767,905.77
非流动资产处置损益合计	71,968.47	168,509.77
非流动资产处置损益合计	345,965.27	287,110.78
非流动资产处置损益合计		

附注五、非经常性损益明细表
 2022年度
 (A股)

五、非经常性损益明细表 (单位: 人民币元)

(三) 其他非经常性损益

项目	本期发生额	上期发生额
1. 非流动资产处置损益		
2. 计入当期损益的政府补助		
3. 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益		
4. 其他		
合计	29,436,207.46	16,275,602.70
减：所得税影响额	458,629.04	
合计	29,894,836.50	16,275,602.70

(四) 其他非经常性损益

项目	本期发生额	上期发生额
1. 非流动资产处置损益		
2. 计入当期损益的政府补助		
3. 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益		
4. 其他		
合计	3,240.59	
减：所得税影响额		
合计	3,240.59	

(五) 其他非经常性损益

项目	本期发生额	上期发生额	本期发生额	上期发生额
1. 非流动资产处置损益				
2. 计入当期损益的政府补助				
3. 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益				
4. 其他				
合计	57,969,287.42	498,871,976.49	488,702,553.33	68,138,710.58
减：所得税影响额	2,518,896.85	30,311,176.43	30,410,434.15	2,419,639.13
合计	60,488,184.27	529,183,152.92	519,112,987.48	70,558,349.71

NE
F 2022 E
(A RMB Y)

V. N ()

() E ()

2. L -

B		I		D		B
I		I		D		B
(1) W	56,230,979.61	447,906,594.96	437,976,426.00	66,161,148.57		
(2) S	87,835.30	10,184,665.65	9,965,118.81	307,382.14		
(3) S	1,334,394.89	19,527,025.66	19,397,236.12	1,464,184.43		
I : M	1,290,685.28	18,813,797.48	18,678,735.17	1,425,747.59		
W	38,841.61	641,567.33	643,107.24	37,301.70		
M	4,868.00	55,652.85	60,096.21	424.64		
O		16,008.00	15,297.50	710.50		
(4) H						

附注		2022		2021	
F		RMB Y		RMB Y	
(A)		(B)		(C)	
V. N					
()					
		B		B	
I.					
VAT		2,399,813.52		2,194,179.27	
E		26,859,279.46		22,060,348.34	
I		1,260,918.02		1,102,372.67	
C		163,205.29		39,305.94	
P		2,292,516.47		4,544,055.56	
E		116,587.33		28,135.83	
L		387,329.69		250,083.20	
S		25,663.04		16,848.52	
E		1,696.00			
40 T					

五、非经常性损益明细表
 2022 年度
 (A 币种: 人民币 Y 币种: 人民币)

V. Non-recurring gains and losses (in RMB)

(in thousands of RMB)

2. Disposal of long-term equity investments

	Balance at the beginning of the year	Balance at the end of the year
I. Disposal of long-term equity investments		
Other income		86,550.00
Disposal of long-term equity investments	735,000.00	
Total	735,000.00	86,550.00

3. Other

	Balance at the beginning of the year	Balance at the end of the year
I. Other		
Participating in the equity of other companies	25,932,146.03	8,703,936.40
Participating in the equity of other companies	7,000,000.00	15,000,000.00
Warrant	3,682,272.62	7,166,038.37
Debt	1,900,552.80	1,094,722.20
Cash	17,695,375.57	7,496,808.30
Prepaid expenses	4,374,261.21	4,312,000.00
Accounts receivable	3,673,024.53	6,981,466.40
Other	6,624,054.06	4,025,654.97
Total	70,881,686.82	54,780,626.64

N
 F
 (A

2022
 RMB Y

F
 J
)

V. N. ()

(III) $\mathcal{A} \subseteq \mathcal{B}$ and $\mathcal{B} \subseteq \mathcal{A}$ are not true.

		B.1.1.1.1	B.1.1.1.2
I.			
L	-	22,470,000.00	18,200,000.00
L	-	99,580,000.00	
L		25,548,324.39	30,040,752.22
T		147,598,324.39	48,240,752.22

(I) L -

NEF 2022
(A RMB Y)

V. N ()

(I) L -

	B	B
I		
L -	42,404,938.54	
S		
T	42,404,938.54	

O : -

	B	B
I		
A	141,984,938.54	
I : U	9,382,772.07	
L : L -	99,580,000.00	
T	42,404,938.54	

(II) D -

	B	I	D	B	R
I					
G	9,341,683.00		303,792.00	9,037,891.00	

附注五、非经常性损益明细表
 2022年度非经常性损益明细表
 (A 币种: 人民币)

五、非经常性损益明细表 (币种: 人民币)

(一) 非经常性损益明细表

项目 金额

1

非流动资产处置损益

非流动资产处置损益

2

公允价值变动损益
 3

4

9,341,683.00

303,792.00

9,037,891.00

5

6

9,341,683.00

303,792.00

9,037,891.00

(二) 非经常性损益明细表

非流动资产处置损益 I (+)/ (-)

非流动资产处置损益

7

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

8

74,600,300.00

公允价值变动损益

公允价值变动损益

9

74,600,300.00

74,600,300.00

(三) 非经常性损益明细表

非流动资产处置损益

非流动资产处置损益

10

非流动资产处置损益

非流动资产处置损益

非流动资产处置损益

11

783,420,735.87

783,420,735.87

12

- 公允价值变动损益

32,642,955.35

12,214,418.85

44,857,374.20

13

- 公允价值变动损益

22,101,704.37

4,698,718.86

26,800,423.23

14

838,165,395.59

16,913,137.71

855,078,533.30

NE
F 2022
(A RMB Y)

V. N ()

(I)C ()

O , : (1) F - , N IX.

(2) I 2022, RMB4,698,718.86 R S R S I P .

()

	B	B	I D B
I			
S	38,399,577.13	38,399,577.13	38,399,577.13
T	38,399,577.13	38,399,577.13	38,399,577.13

O :

I C L P ' R C , C 10%
T C
50% T
- -

W
F
(A)

2022
RMB Y)

E
J

附注五、非经常性损益明细表
(A股) 2022年度
(人民币元)

五、非经常性损益明细表 (元)

(续)

1. 非流动资产处置损益

项目	2022年度	2021年度	2020年度	2019年度
处置固定资产、无形资产和其他长期资产的损益	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
处置子公司、参股公司和其他权益工具的损益	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
合计	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

2. 公允价值变动损益

项目	2022年度	2021年度
交易性金融资产	1,366,816,938.51	1,202,774,377.74
交易性金融负债	305,118,303.27	267,588,282.25
其他权益工具投资	1,061,698,635.24	935,186,095.49
其他非流动金融资产	118,086,103.74	94,655,992.09
其他	85,464,736.39	51,613,429.22
合计	3,000,000.00	2,970,297.00
其他	8,067,969.32	7,515,329.40
其他	16,043,547.63	16,043,547.63
其他	21,553,398.03	16,513,388.84
合计	1,484,903,042.25	1,297,430,369.83

2. 公允价值变动损益

其他非流动金融资产

N		F	
F		2022	
(A		RMB Y	
V. N		(	
(		A	
I		A	

NE
F (A 2022 RMB Y)

V. N ()

(L)G

I	A	A
E	106,839,736.87	92,095,322.35
C	22,821,067.41	11,791,502.03
D	12,364,390.29	10,327,372.91
R	7,928,268.21	7,688,976.40
A	7,169,511.48	7,803,052.34
A	6,366,300.00	1,222,900.00
O	5,452,608.66	5,171,123.31
A	5,226,706.30	3,986,627.45
E	4,539,506.45	2,946,383.00
E	4,412,652.14	8,414,462.03
T	4,358,637.42	2,835,174.29
P	2,798,524.34	3,204,882.36
H	2,653,266.15	4,644,062.36
G	2,527,587.52	3,580,020.08
P	2,521,353.37	1,319,556.59
O	2,099,610.09	3,313,286.64
U	1,889,937.19	1,974,023.35
P		96,657.59
O	3,917,508.51	3,956,503.74
T	205,887,172.40	176,371,888.82

附注五、非经常性损益明细表
 2022年度
 (A 币种:人民币)

五、非经常性损益明细表 (单位:元)

(续)

	2022年度	2021年度
一、非流动资产处置损益		
处置固定资产损益	29,575,455.47	24,627,424.22
处置无形资产损益	1,164,368.95	1,346,035.33
处置长期股权投资损益	550,065.23	594,882.24
处置其他非流动资产损益	400,114.92	311,882.70
处置其他非流动资产损益	76,467.92	
处置其他非流动资产损益	68,877.00	134,907.60
处置其他非流动资产损益	58,690.00	
处置其他非流动资产损益	30,200.00	
处置其他非流动资产损益	19,682.96	76,999.34
处置其他非流动资产损益	11,090.48	
处置其他非流动资产损益	3,000.00	
处置其他非流动资产损益	1,069,974.86	870,041.96
二、其他非经常性损益	33,027,987.79	27,962,173.39

(续) 非经常性损益明细表

	2022年度	2021年度
一、非流动资产处置损益		
处置固定资产损益	45,149,998.30	36,267,756.91
处置无形资产损益	11,935,506.62	14,290,203.16
处置长期股权投资损益	2,761,765.05	1,691,366.88
处置其他非流动资产损益	-78,462.87	38,704.15
处置其他非流动资产损益	1,999,946.76	3,043,331.77
二、其他非经常性损益	44,309,717.14	37,658,425.95

NE
F (A 2022 RMB Y)

V. N ()

(LIII) O

I	A	A
G	14,602,195.91	13,486,446.80
A VAT	37,171.75	
F	162,213.15	133,188.26
O	106,130.00	
T	14,907,710.81	13,619,635.06

I	A	A	A - /
T	859,807.09	1,231,900.37	I -
S T	3,408,933.78	3,325,154.99	I -
S	1,018,900.00	2,270,000.00	I -
E S S B H R	973,813.11	244,079.31	I -
I D R B G C 2021	638,519.98		I -
S	600,000.00	50,000.00	I -
S	600,000.00		I -
V COVID-19	440,197.00	814,795.52	I -
S H C	311,520.00	744,608.99	I -
R B W F	303,792.00	303,792.00	A -
S	300,000.00		I -
B H P B	284,000.00	284,000.00	I -
S	249,000.00		I -
S H B Y 2021	238,400.00		I -

NE
F 2022
(A RMB Y)

V. N ()

(LIII) O ()

G ()

I	A	A	A - /
H COVID-19			
H C P	197,750.00		I -
H C C	174,653.70		I -
U S B B H R			
S S	138,796.96		I -
O S	120,835.00		I -
S	117,625.00		I -
W - D H			
S C	64,000.00		I -
H B Y D ,H	63,971.59		I -
I R B P	55,332.00	50,000.00	I -
S I P	50,000.00		I -
S	90,000.00	168,696.99	I -
S D P ' H	40,000.00	40,000.00	I -
T M F S A T			
	38,201.19		I -
E	36,218.55		I -
T 2022			
E I B Y C	22,045.69		I -
S F B N M B P A	20,000.00		I -
T - P B			
W E E B	20,000.00		I -
T -			
H C L D	20,000.00		I -
T - C B			
W E E B	20,000.00		I -

NE
F (A 2022 RMB Y)

V. N ()

(LIII) O ()

G ()

I	A	A	A - /
R C			
D C P	17,000.00		I -
S			
E C J D	13,610.61		I -
W L D D R B ' E			
R I P	12,000.00		I -
Y C H B ' S P H S F	10,200.00	13,500.00	I -
W M H C ' F Y M			
T	7,000.00		I -
W M H C ' H R			
T F	6,700.00		I -
S W H P F M C	4,433.33		I -
P C H B ' S F	3,000.00	1,904,299.94	I -
L C C D C P ' F M			
S	3,000.00		I -
W H P F M C ' H			
P F S	1,833.33		I -
Y D P D ' F R			
C R , D B	1,600.00		I -
E A S	1,500.00	74,237.34	I -
M S	1,380.00		I -
P H S F L D H C	1,000.00		I -
P C P F E M - -C			
T HIV, S, H B	476.00		I -
P C P F F P B D			
P	450.00		I -
O D M S A ' S			
M A D R	360.00		I -

NE
F 2022 F
(A RMB Y)

NE
F (A 2022 RMB Y)

V. N ()

(I) G

	A	A
F 2,054,396.53	8,407,356.31	
I : G 13,922,929.38		
F 13,922,929.38		
I 1,010,034.42		
T 15,977,325.91	9,417,390.73	

(I I) C

	A	A
I		
L 11,260,563.08	3,005,695.74	
L 13,930,978.11	-865,499.29	
T 25,191,541.19	2,140,196.45	

(I II) A

	A	A
I		
G 10,345,460.56	6,179,290.37	
T 10,345,460.56	6,179,290.37	

附注五、非经常性损益明细表
 F
 (A 2022 RMB Y)

V. N ()

(I, III) G					A	-
I.					A	
G	-					
(	-					
I : G						
(	-					
O						22,109.35
T						

(II) N -					A	-
I.					A	
G						
-						
I : F						
D						
G						
G						
P						
D						
V						
U						
O						
T						

NE
 F (A) 2022 RMB Y ()

V. N ()

(L) N - ()

G -

	A	A	A - /
I			-
S W - W 2021		100,000.00	I -
P D P			
H		150,000.00	I -
S D I S	5,000.00		I -
F C A D R			
M R D	75.00		I -
E T C A	5,000.00		I -
S B L E H	40,000.00		I -
S B L E H	5,000.00		I -
I F P H B		15,600.00	I -
T	55,075.00	265,600.00	

(L) N -

A

	A	A	
I			
L	1,587,610.46	165,976.73	1,587,610.46
I : F	1,587,610.46	165,976.73	1,587,610.46
E	3,927,631.03	3,333,396.94	3,927,631.03
	521,375.57		521,375.57
L	99,809.90		99,809.90
P	267,628.43		267,628.43
L	1,754,450.54	3,398,511.21	1,754,450.54
O	1,182,532.80	1,738,698.54	1,182,532.80
T	9,341,038.73	8,636,583.42	9,341,038.73

N		F		E	
F		2022		2021	
(A)		RMB Y		RMB Y	
V. N				()	
(LI) I					
1. T					
				A	A
I					
C				40,192,565.61	26,919,820.08
D				-13,618,853.12	

V. N. ()

1. $B \rightarrow C$

	A	A
I		
C	-24,220,782.31	44,035,995.21
W	74,600,300.00	72,140,300.00
B	-0.32	0.61
I	-0.32	0.61

2. D

I		A	A
C		-24,220,782.31	44,035,995.21
W		74,600,300.00	74,600,300.00
D		-0.32	0.59
I		-0.32	0.59

	A	B
E	538,910,495.15	435,967,572.12
P	417,971,255.04	353,105,992.03
C		15,204,373.00
D	53,029,785.07	45,173,131.23
D	38,189,335.84	45,435,380.70
A	22,991,163.56	15,010,629.62
A	46,397,646.59	38,371,918.45
H	17,904,619.09	15,472,884.97
C	66,553,544.09	57,050,465.71
U	29,928,936.30	24,096,157.46
O	23,086,080.63	21,047,712.17
T	27,657,239.14	25,603,836.37
C	28,302,685.02	13,820,361.56
A	6,366,300.00	1,222,900.00
P	3,526,992.98	2,990,339.08
T	5,332,487.78	4,416,545.06
O	8,492,200.89	9,312,807.52
S	12,214,418.85	15,932,752.35
O	39,035,944.67	43,866,151.22
T	1,385,891,130.69	1,183,101,910.62

NEF 2022
(A RMB Y)

V. N ()

(LI) I

1. G

I	A	A
R	40,253,328.59	45,945,728.57
G	14,633,117.41	13,579,087.19
L	8,067,969.32	7,012,773.24
D	10,116,855.54	12,851,693.57
I	12,751,158.99	14,960,534.77
N -	1,035,391.18	1,870,927.58
R	14,000,000.00	
T	100,857,821.03	96,220,744.92

2. G

I	A	A
I -	30,632,892.49	23,313,110.97
C	82,155,141.49	54,235,967.08
D	6,608,712.31	6,714,560.33
N -	2,927,440.32	4,469,403.02
F	1,082,364.51	1,442,594.04
R	12,498,972.00	
T	135,905,523.12	90,175,635.44

3. G

I	B	B
N	8,770,704.43	
T	8,770,704.43	

  F 2022 (A RMB Y)			
V. N			
(LI) I			
4. G			
		A	A
I			
G		150,684,059.10	
G		736,190.90	
T		151,420,250.00	
5. G			
		A	A
I			
G		8,096,992.56	
G		43,524,302.81	44,807,765.61
F		4,500,000.00	750,000.00
G			15,118,800.00
T		56,121,295.37	60,676,565.61

附注
 2022
 RMB Y

V. N ()

(L) 1. S

	A	A
1. R		
N	-10,968,838.36	40,860,230.05
A : C	25,191,541.19	2,140,196.45
P	10,345,460.56	6,179,290.37
D	53,029,785.07	48,274,868.81
C		
D	38,189,335.84	41,779,572.06
A	22,991,163.56	14,530,192.10
A	46,397,646.59	38,836,785.71
L		
()	-406,184.95	79,403.55
L	1,574,873.04	11,373.31
L	15,977,325.91	-9,417,390.73
F	45,071,535.43	36,306,461.06
I	-2,850,458.27	-6,937,845.27
D	-6,345,432.93	27,745,384.58
I	672,088.86	14,843,351.28
D	-1,812,096.14	-19,010,829.84
D	-137,055,559.27	-37,743,452.80
I	127,218,378.32	-4,581,092.21
O		
N	227,220,564.45	193,896,498.48
2. S		
C		
C		
F		
3. N		
G	258,595,990.97	188,734,845.77
L : G	188,734,845.77	200,092,665.42
A : G		
L : G		
N	69,861,145.20	-11,357,819.65

NEF 2022
(A RMB Y)

V. N ()

(L)

2. N

A

G	54,309,855.16
I :J S H C .,L .	21,684,900.00
Y Y TCM- H C .,L .	32,624,955.16
L :C	624,153.88
I :J S H C .,L .	624,153.88
Y Y TCM- H C .,L .	
A :C	
O	53,685,701.28

3. C

I	A	A
I. G	258,595,990.97	188,734,845.77
I :C	454,907.26	971,773.72
D		
C	257,534,338.59	187,484,938.31
O	606,745.12	278,133.74
D		
D		
L		
II. C		
I :B		
III. C	258,595,990.97	188,734,845.77
I :U		
G		

NEF 2022
(A RMB Y)

V. N ()

(L I) A C

I	R
M 498,972.00	Ba P
12,000,000.00	
F 35,612,151.67	C
73,406,248.95	Sa
I 6,107,838.02	C
T 133,942,408.61	

(L II) G
P N V (XLIII) N V (XLIX)

VI. C

(I) B
1. B

C P
N (%)

附注		2022	2021
F		RMB Y	
(A)			
VI. C		()	
(I) B		()	
2. C			
		Y	Y J Y S Z F

NEF
F (A 2022 RMB Y)

VI. C ()

(I) B ()

2. C (C)

(2) I J 2022, Z K H M (G) C L (Z K), C C J Y X , Z F N T C , L . (Z F), S ' A Z F N T C , L , C RMB3,000,000.00 RMB2,673,987.56 Z F , RMB326,012.44.

3. I ()

	Y	Y	J S	Z F
	Fe	Ge	Fe	Ge
A :	59,544,389.38	46,544,389.38	37,912,065.31	21,595,600.11
G			624,153.88	624,153.88
R	3,060,406.64	3,060,406.64	7,552,399.46	7,552,399.46
I			505,619.01	504,706.60
O			22,965.97	22,965.97
F	4,043,853.80	4,043,853.80	847,808.30	394,720.51
C			6,651,653.69	6,651,653.69
I	13,299,835.09	299,835.09	15,862,465.00	
L -	24,864,697.08	24,864,697.08		
O -	14,275,596.77	14,275,596.77	5,845,000.00	5,845,000.00
L :	17,960,741.79	17,960,741.79	8,244,110.73	4,164,994.43
B				422,980.00
P	14,710,741.79	14,710,741.79	4,099,565.00	261,041.74
E			618,827.28	159,133.43
T			-553,397.85	2,804.83
D	3,250,000.00	3,250,000.00	4,079,116.30	
N	41,583,647.59	28,583,647.59	29,667,954.58	3,173,987.56
L :			15,130,745.84	500,000.00
N	41,583,647.59	28,583,647.59	14,537,208.74	2,673,987.56

M : T C

VI. C $\clubsuit$ ()

(II) D,

1. L

D

MB Y 

F

A

D

C

B

M

7

HY

N

•

• **•** **•** **•** **•**

O 10 A 2022, Z K₂ H C M (G) C₂L (C₂L F Z
K₂), C₂L C J M H S I₂E F
P₂(L P₂), C J P IIM H S I₂E F
P₂(L P₂) T₂ W L₂H₂M₂ C₂L (C₂L₂ L₂
L₂L₂L₂) S₂, A H₂ Y H C₂L₂ L₂L₂
Z K₂ 28% L₂L₂L₂ ,
RMB14,000,000.00, L₂L₂L₂ ,
RMB13,922,929.38, H₂ Y H C₂L₂ .
A 10, 2022.

NE
F 2022 F
(A RMB Y)

VI. C ()

(III) C

T Z H H RMB7.23 . A
, C 47.48% Z H H

VII.I

(I) I

1. S G

N P P N (0000') D I M

NEF
F (A) 2022 RMB Y ()

				占 比 (%)		
名称	经营范围	注册资本	实收资本	持股比例	(0000')	董 监 高
W C H 科 C.,L . LLC	W	W	M 科 科	2,585.98	100.00	B 科
						W 科 J 科F

F
(A

2022
RMB Y

F

VII.I ()

(I) ()

3. M	C	N	B	C	N	C	N	T	C	N	T
------	---	---	---	---	---	---	---	---	---	---	---

W L											
Y H											
C., L.	19,028,799.19	98,436,498.17	117,465,297.36	20,546,971.67	45,000,000.00	65,546,971.67	17,869,229.47	32,881,657.54	50,750,887.01	3,824,900.47	3,824,900.47
B Y											
H C., L.	10,169,979.61	8,898,422.97	19,063,352.58	14,398,845.02	1,002,833.33	15,396,678.35	3,758,467.94	15,734,695.01	19,493,162.95	8,026,455.59	2,551,303.77
S Y											
H	14,488,059.45	19,086,594.25	33,574,653.70	34,702,233.46	5,720,723.50	40,422,976.96	11,484,646.25	30,441,596.64	41,926,242.89	29,993,444.43	12,842,112.65
											42,834,557.08

A	C	R	N	T	G
---	---	---	---	---	---

W L	Y H	C., L.									
B Y	H	C., L.									
S Y	H										

NE
F 2022
(A RMB Y)

VIII. R

D , C : ,
(,). T
C :

T C ,
C . T C
C . T
, . T C
C
. T C S R M C
. T S R M C
,
C T C A C .

T C
 ,
 .

(I) C

C C

T C , , , .

T C -
 - . T C
 .

VIII. R ()

(I) C_{max} (mg/L)

T C A F T C F T C A B D P F T C

(II) L

L
 I
 C
 C
 B
 C
 12
 A
 V
 C
 :

C B

I

I	1	1-2	2-5	0-5	6
N	997,944.00				997,944.00
B	211,396,818.18	223,154,176.00	153,052,040.00	69,285,680.00	656,888,714.18
L	99,580,000.00	28,954,752.75	26,076,534.51		154,611,287.26
T	311,974,762.18	252,108,928.75	179,128,574.51	69,285,680.00	812,497,945.44

附注八、其他非流动资产
2022 年 12 月 31 日余额 254,050,000.00 元

其他非流动资产 254,050,000.00 元

(二) 其他非流动资产

其他非流动资产		2022 年 12 月 31 日余额		2021 年 12 月 31 日余额	
项目	账面余额	减值准备	账面价值	项目	账面余额
预付账款	254,050,000.00		254,050,000.00	预付账款	254,050,000.00

2022
 RMB Y ()
 VIII. R ()
 (III) M ()

NE F
(A 2022 RMB Y)

VIII. R ()

(III) M ()

3) O

O

T C

O 31 D 2022, RMB1,893,506
RMB1,893,506, 3%, 3%

IX. D

T

L 1 () C

L 2 L 1

L 3

T

IX. D

(I) C

I.	C			D.
	M	L	M	
		1	2	3
I. C				
◆ F				10,641,026.00
1. F				10,641,026.00
(1)				
(2) I				10,641,026.00
(3)				
2. F				
T				10,641,026.00
◆				13,922,929.38
1.				13,922,929.38
(1)				
(2)				
(3)				13,922,929.38
2. F				
T				13,922,929.38

(II) Q_{-}

[illegible]

NE
F 2022
(A RMB Y)

X. R

() I
T C :G W ,W L

() I C ,
D C N VII.I

() I C ,
F C , N VII.I

T
C

N C

C	H K H C ,L	A	C
W	A P C ,L	A	C
C	Y H C ,L	A	C
H	Y H C ,L	A	C

X. R ()

(I) I

$\frac{N}{M} \cdot H$	C
$Y = M \cdot H \cdot C$	$N = \frac{C}{H} \cdot \frac{M}{C}$
$N = M \cdot B \cdot P \cdot A \cdot K \cdot \dots$	$P = \frac{C}{B} \cdot \frac{A}{C} \cdot \frac{K}{C} \cdot \dots$
$I = \frac{M}{P} \cdot \frac{P}{M}$	$C = \frac{A}{B} \cdot \frac{K}{C} \cdot \dots$
$(L \cdot L \cdot P)$	
$N = F \cdot T \cdot Z \cdot S$	
$I = \frac{T}{S} \cdot \frac{Z}{C} \cdot \frac{F}{L}$	
$S = \frac{F}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$	$N = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
$C = \frac{L}{S} \cdot \frac{S}{L}$	
$W = L \cdot \frac{S}{C}$	$N = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
$Q = K \cdot \frac{C}{L}$	$N = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
$W = H \cdot \frac{C}{L}$	$D = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
	$N = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
$Z = \frac{C}{T} \cdot \frac{T}{E} \cdot \frac{C}{L}$	$N = \frac{C}{H} \cdot \frac{M}{C} \cdot \frac{C}{L}$
$C = \frac{L}{S} \cdot \frac{S}{L}$	

() I

1. $R \rightarrow R \otimes R \rightarrow R \otimes R \otimes R \rightarrow \dots$
 $S \rightarrow S \otimes R \rightarrow S \otimes R \otimes R \rightarrow \dots$

C		A	A
Y	M	3,000,000.00	3,000,000.00
C	H	71,199.48	
W	A	54,281.47	456,272.70
J	S		2,372,524.98
R			682,184.79

[illegible]

NE
F (A 2022
RMB Y)

X. R ()

() I ()

3. R
T C :

		G	C		
N				E	
Y K H C ,L		50,200,000.00	2019/8/26	2029/8/20	N
Q K H C ,L		45,000,000.00	2019/12/31	2024/12/31	N

T C

		G	C		
N				E	
G W W L		30,000,000.00	2020/6/30	2027/6/30	N
G W , W H					
W L		75,000,000.00	2021/11/29	2028/11/29	N
G W , W H , W L					
X		150,000,000.00	2020/10/26	2026/10/25	N
G W , W L					
W H		200,000,000.00	2020/9/17	2023/9/17	N

4. A
C A
9

NE
F 2022 F
(A RMB Y)
X. R ()

NE
F (A 2022 RMB Y)

X. R ()

(II) E

I 2022, , :

C

O

N	E	B	O
E			
G W	413,976.00	70,950.72	79,754.00
W L	516,000.00		96,000.00
W H	231,450.00	50,888.16	600.00
N			
Q H			
L C			
I			
Z X	70,000.00		70,000.00
Z W	70,000.00		70,000.00
L N	70,000.00		70,000.00
Q C			
X Y			
S F			
X N	313,320.00	56,939.80	36,000.00
X T	98,760.00	40,146.72	67,954.00
T	210,000.00	1,573,506.00	218,925.40
		279,708.00	109,285.45
			2,391,424.85

O :

O S 1, 2022, W H , C ; F 19, 2022, S F , C X N .

附注五、营业收入和营业成本
 2022年度营业收入和营业成本
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

X. R ()

(II)E (C)

I 2021, , , , :

C

项 目	数 额	数 额	数 额	数 额	数 额	数 额
一、营业收入						
主营业务收入						
药品销售收入	-	398,742.00	15,795.90	78,916.40	4,300.00	497,754.30
医疗服务收入	-	375,592.00	-	46,714.60	44,680.00	466,986.60
其他医疗服务收入	-	208,108.00	-	42,396.60	1,200.00	251,704.60
其他业务收入						
租金收入	-	-	-	-	-	-
其他收入	-	28,200.00	4,986.80	32,385.97	8,932.90	74,505.67
二、营业成本						
主营业务成本						
药品销售成本	70,000.00	-	-	-	-	70,000.00
医疗服务成本	70,000.00	-	-	-	-	70,000.00
其他医疗服务成本	70,000.00	-	-	-	-	70,000.00
其他业务成本						
折旧费	-	-	-	-	-	-
职工薪酬	-	-	-	-	-	-
其他费用	-	-	-	-	-	-
其他成本	-	-	-	-	-	-
其他业务成本	-	82,613.40	8,885.40	54,030.60	18,936.60	164,466.00
三、利润总额	210,000.00	1,093,255.40	29,668.10	254,444.17	78,049.50	1,665,417.17

附注五、非经常性损益
F (A 2022 RMB Y)

X. R ()

(III) F I H

I 2022, 2 (2021: 3),

I	A	A
W, ,	3,764,039.10	3,424,382.50
S -	4,109,519.26	4,411,564.18
T	7,873,558.36	7,835,946.68
	N	N
500,000-1,000,000.00	1	1
1,000,000.00	4	4
T	5	5

NE
F 2022
(A RMB Y)

XI. S -

(I)

T C :

O J 13, 2018, C , 2018 W
K H E P 2018, B C
T B C P G R
S I O J 29, 2018 A 20, 2018, T C
W Z K I
M P (L L P), W J K I M
P (L L P), W E K I M P
(L L P), W J K I M P (L
L P) W S K I M P (L
L P), 2,460,000

XI. S $\frac{1}{2}$ - $\frac{1}{2}$ $\frac{1}{2}$ ()

(II) E = -

M :

M :

附注
 F
 (A 附注
 2022
 RMB Y 附注)

XII.C 附注 C

(I) 附注

1. C 附注 附注 附注

NE
F 2022
(A RMB Y)

XIV. C

T C
— C
—
T C . T . I
C
T C
A C :

B		B
D /		49.73% 46.16%

NEF (A 2022 RMB Y)

XV. O

(I) C

R
A 38 M T S B D E M T
S S C C P R C P
A E ,
2021 :

C	P	A	C
I	B R	O	-9,203,741.45
		I	12,877.91
		U	9,190,863.54

(II) I

E C
D
C
A C W G I J 2021, C

(III) O

1. I
O A 14, 2023, 38 B D W K
H C , L ,










 F 2022
 (A RMB Y)
 XV. O ()

(III) O ()

1. I ()

(1) I RMB14.43

B S 2022, I
 I A ,
 2019 2020 RMB14.43 , RMB5.25
 RMB9.18 , T
 K H ,
 I I C B D ,
 (I) 2021, N XV

(2) R S W D C

A C
 RMB2,190,700, C
 C
 T C
 C
 C




 F 2022
 (A RMB Y)

XV. O ()

(III) O ()

1. I ()

(3) R

Ba
 S 2022,
 :

① Pa : I C C
 , C
 ,
 . A
 C
 .

② A : Ba
 C C
 , ,
 C
 C . T

NE F
F (A 2022 RMB Y)

XV. O ()

(III) O ()

2. A ()

(2) I 12 2019, 2020 2021 C
2020 2021
C 2020 2021, T
RMB428,900 2020 RMB335,100 2021, C
C
2020 2021.

(3) O , C 2022

XVI. N

(I) A

1. A

A	B	Ba
W 1	49,024,983.98	40,904,137.67
1-2	709,878.26	1,282,268.26
2-3	1,158,221.95	2,748,299.92
O 3	2,748,299.92	1,204,242.08
S	Over 3 years	1,158,221.95

XVI. N


(I) A

2. A

C	B		P		B		P		B		P	
	A	(%)	A	(%)	B	(%)	A	(%)	B	(%)	A	(%)
A	4,873,715.26	9.09	4,873,715.26	100.00			5,315,384.45	11.52	2,657,692.23	50.00	2,657,692.22	
I :												
M	4,873,715.26	9.09	4,873,715.26	100.00			5,315,384.45	11.52	2,657,692.23	50.00	2,657,692.22	
A	48,767,668.85	90.91	48,767,669	1.00	48,279,992.16	88.48	40,823,563.48	88.48	408,235.63	1.00	40,415,327.85	
I :												
O	48,767,668.85	90.91	48,767,669	1.00	48,279,992.16	88.48	40,823,563.48	88.48	408,235.63	1.00	40,415,327.85	
T	53,641,384.11	100.00	5,361,391.95		48,279,992.16	100.00	46,138,947.93		3,065,927.86		43,073,020.07	
A												
I												
M			4,873,715.26		4,873,715.26	100.00						
T			4,873,715.26		4,873,715.26							

XVI, N         

(I) **A** _____ (_____)

2. A  $(\quad)$

A      :

B

	A	P	P	
I	0.0000	0.0000	0.0000	(%)

O	48,767,668.85	487,676.69	1.00
T	48,767,668.85	487,676.69	


3. $P \nVdash \Box \neg \Box \neg P$, $\Box \neg \Box \neg P \nVdash P$

C

NEF 2022
(A RMB Y)

XVI. N ()

(II) O		B	B
I			
I			
D		53,000,000.00	
O		547,014,558.58	492,034,884.26
T		600,014,558.58	492,034,884.26
1. D		B	B
G K H C , L		33,000,000.00	
Y K H C , L		10,000,000.00	
Q K H C , L		10,000,000.00	
S		53,000,000.00	
L : P			


F
(A)

2022
RMB Y

)

(

(
)

)

)

)

)

(

(

)

XVI, N

(II) O

NEF 2022
(A RMB Y)

XVI. N ()

(II) O ()

(3) P V

	1 L ECL	2 L ECL	3 L ECL
12- ECL	(N (C -	(N (C -	(N (C -
P			
B	123,061.04		123,061.04
B			
-T			
-T			
-R			
-R			
P	103,420.62		103,420.62
R			
W			
W			
O			
B	226,481.66		226,481.66

C V V :

	1 L ECL	2 L ECL	3 L ECL
12- ECL	(N (C -	(N (C -	(N (C -
B			
B	492,157,945.30		492,157,945.30
-T			
-T			
-R			
-R			
A	55,083,094.94		55,083,094.94
D			
O			
B	547,241,040.24		547,241,040.24

NEF 2022 F
(A RMB Y)

XVI. N ()

(II) O ()

(4) P , B C R W B

C	P	
P	123,061.04	103,420.62
T	123,061.04	103,420.62

(5) O B B

A	507,207,052.64	481,560,443.31
P	33,132,118.55	8,954,970.91
D	5,933,350.00	854,300.00
O	968,519.05	788,231.08
T	547,241,040.24	492,157,945.30

NEF
F (A 2022 RMB Y)

XVI. N ()

(III) L -

I	B		B		B	
	P		P		P	
	B	B	B	B	B	B
I	649,079,592.72	649,079,592.72	613,070,215.90		613,070,215.90	
I	92,882,992.81	92,882,992.81	71,256,356.09		71,256,356.09	
	741,962,585.53	741,962,585.53	684,326,571.99		684,326,571.99	

1. I

I	B		B		B	
	I		D		I	
S Y M I C ,L .	10,354,979.06				10,354,979.06	
Z H H M C ,L .	34,627,432.36		34,627,432.36			
W K J F C	500,000.00				500,000.00	
Z K H M C ,L .	203,344,031.86	1,322,222.01			204,666,253.87	
C K H C ,L .	51,982,515.15	715,222.35			52,697,737.50	
Y K H C ,L .	1,832,112.13	301,146.25			2,133,258.38	
Y K H C ,L .	27,447,511.21	239,581.90			27,687,093.11	
Q K H C ,L .	32,626,079.15	230,565.10			32,856,644.25	
L K H C ,L .	2,110,854.98	188,216.41			2,299,071.39	
W C H C ,L .	53,500,000.00				53,500,000.00	
W L Y H C ,L .	30,000,000.00				30,000,000.00	
W O Y R H C ,L .	10,000,000.00				10,000,000.00	
P C Y H C ,L .	154,744,700.00				154,744,700.00	
J S H C ,L .		26,684,900.00			26,684,900.00	
Y Y T						
W M H C ,L .		40,954,955.16			40,954,955.16	
T	613,070,215.90	70,636,809.18	34,627,432.36		649,079,592.72	

F
 (A 2022 RMB Y)

B



A

III





I

XVI. N

(III) L

2.

附注五、营业收入和营业成本
2022年度营业收入和营业成本按产品类别披露如下：

XVI. 营业收入和营业成本按产品类别披露如下：

(I)

1. 营业收入和营业成本按产品类别披露如下：	营业收入	营业成本	营业收入	营业成本
主营业务收入	337,586,514.02	264,978,847.50	365,462,139.23	270,930,179.07
其他业务收入	5,554,936.61	45,300.00	4,336,166.89	559,209.63
合计	343,141,450.63	265,024,147.50	369,798,306.12	271,489,388.70

营业收入按地区披露如下：

营业收入	营业收入	营业收入
主营业务收入	90,612,303.06	93,506,118.66
其他业务收入	246,974,210.96	271,956,020.57
合计	337,586,514.02	365,462,139.23

2. 营业成本按地区披露如下：

(II)

营业成本	营业成本	营业成本
主营业务收入	54,584,000.00	1,980,000.00
其他业务收入	-5,377,605.11	-3,485,811.81
合计	-18,462.42	
合计	714,348.18	6,429,189.35
合计	49,902,280.65	4,923,377.54

Definitions

AGM	Annual General Meeting of the Company	C 2022
A	Shareholder	C
A C	Shareholder	B
B Y H	B Y H C ., L . (北京怡寧醫院有限公司), PRC A 17, 2015, C	
B D B	B C	C
C K H	C K H C ., L . (蒼南康寧醫院有限公司), PRC J 15, 2012, C	
CG C	C G C A 14 H K L R	
C K P H	C K P H C ., L . (長春康林心理醫院有限公司), PRC F 16, 2016, C	
C K H	C K H H C ., L . (淳安康寧黃鋒醫院有限公司), PRC A 16, 2020, C	
C W K H	W K H C ., L ., PRC, H S M B H K S E (S C : 2120)	
C S	H K L R M . GUAN W M . WANG L	

Definitions

CSRC	中國證券監督管理委員會
D ()	董事會
D S ()	董事會秘書 () RMB1.00 元, RMB 元 S
G H	溫州怡寧老年醫院有限公司, PRC N 2, 2015, C
G	C
G Y H	G Y H C ., L . (冠縣怡寧醫院有限公司), PRC M 1, 2017, C
HS ()	香港證券交易所有限公司, RMB1.00 元, M B
H C H	H C H C ., L . (杭州慈寧醫院有限公司), PRC N 18, 2017, C
H Y H	H Y H C ., L . (杭州怡寧醫院有限公司), PRC A 25, 2016, C - . O J 30, 2022, C 28% H Y H T W L L H M C ., L . (桐鄉烏鎮蓮芯蓮意 健康管理有限公司). U 33% H Y H
H Y H	H Y P H C ., L . (荷澤怡寧精神病醫院有限公司), PRC A 6, 2017, C
HK\$ HKD	香港

Definitions

H K

H K S A R

PRC

H K L R

Definitions

Ningbo Yuhang Hospital	Ningbo Yuhang Hospital Co., Ltd. (南京怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at [address]
Ningbo Yuhang Hospital Co., Ltd.	Ningbo Yuhang Hospital Co., Ltd. (寧波怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at [address]
Ningbo Yuhang Hospital Co., Ltd. (A)	Ningbo Yuhang Hospital Co., Ltd. (寧波怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at [address]
Pudong Yuhang Hospital	Pudong Yuhang Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a company incorporated in the PRC on September 3, 2018, with its registered office at [address]
PRC Company	PRC Company, a company incorporated in the PRC, with its registered office at [address]
PRC Company (L)	PRC Company (L), a company incorporated in the PRC, with its registered office at [address]
P	P, a company incorporated in the PRC, with its registered office at [address]
Qingting Kangning Hospital	Qingting Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a company incorporated in the PRC on April 1, 2011, with its registered office at [address]
Qingting Yuhang Hospital	Qingting Yuhang Hospital Co., Ltd. (衢州怡寧醫院有限公司), a company incorporated in the PRC on November 20, 2015, with its registered office at [address]

Definitions

T R P R P	31, 2022
R C	B
RMB	PRC
SFO	(C 571 L H K),
S ()	S () C RMB1.00 , D S () H S ()
S ()	() S ()
S Y H	S Y H (深圳怡寧醫院, S Y H C ., L . (深圳市怡寧醫院有限公司)), PRC S 22, 2014, C - H K L R
S R M C	B
	C O (C 622 H K)
	H K L R
S ()	S C
S C	C S C PRC C I
T K H	T K H C ., L . (台州康寧醫院有限公司), PRC J 30, 2016, C - H K L R

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院有限公司), PRC J 20, 2018, C - T1 T -05.4175 -30538T (°)T 0.556 -0.

